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Serotonin, arising from neurons of the raphe nuclei, is intimately involved in the 
treatment of depression and anxiety disorders.  Serotonin selective reuptake inhibitors (SSRIs) 
are frontline therapy for both of these conditions, and have well-described behavioral effects in 
animal models of emotional behavior.  Yet, administration of SSRIs during postnatal 
development produces an opposing phenotype, including increased anxiety- and depression-like 
and reduced social behaviors.  Because the serotonin transporter, the target of these drugs, is 
expressed primarily in serotonergic neurons of the raphe, I sought to identify biological 
mechanisms for behavioral effects of both adult and postnatal SSRI treatment in this cell 
population.  
Initially, we compared the transcriptome of serotonergic neurons to whole brain 
homogenate, in order to both validate the experimental methods, and to provide a descriptive 
analysis of gene expression in this neuron type.  Many transcripts were enriched in raphé 
samples, including both known markers of serotonergic neurons, and novel genes, most of which 
could be confirmed from by in situ hybridization data from the Allen Brain Atlas. 
In postnatal fluoxetine treated mice, we report alterations at the anatomical, 
electrophysiological, and transcriptional levels.  Serotonergic innervation of the prefrontal cortex 
and hippocampus was reduced by fluoxetine treatment, consistent with the neurodevelopmental 
role serotonin plays.  The firing rate of serotonergic neurons was also reduced due to an increase 
in inhibitory transmission.  Additionally, the transcriptome of serotonergic neurons was altered 
by postnatal SSRI: a preponderance of downregulated transcripts was observed, particularly 
among genes involved in mitochondrial and ribosomal function. These findings combine to 
suggest a hypotrophic serotonergic system is produced by postnatal SSRI treatment. 
Studying the effect of adult treatment with SSRIs, we report a normalization of elevated 
serotonin 1A receptors in depressed, medication-naive patients.  However, we did not detect a 
relationship with clinical response, raising the possibility that serotonin 1A downregulation is an 
epiphenomenon of SSRI treatment.  In adult fluoxetine treated mice, gene expression profiling 
identified a number of differentially regulated transcripts.  We further used postnatal fluoxetine 
treatment as a model of treatment resistance, investigating the transcriptional actions of adult 
fluoxetine treatment in postnatal fluoxetine- vs. saline-treated mice, in order to identify 
transcripts that track with behavior.  We found upregulation of a number of promising candidate 
genes, including vesicular glutamate transporter 3, histamine receptor 2, and the neuropeptide 
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 Serotonin (5-hydroxytryptamine; 5-HT) is a substituted indole present in nearly every 
eukaryotic organism (Azmitia, 1999).  The ancient origins of serotonin are made clear by 
analysis of the molecular phylogeny of the 5-HT1A receptor, which reveals that the earliest forms 
arose as much as one billion years ago (Peroutka and Howell, 1994), possibly even predating the 
first animal species.  In plants, serotonin (and related tryptophan derivatives such as melatonin 
and auxins) are critically involved in trophic responses, and circadian and seasonal rhythms.  
In mammals, serotonin has been demonstrated to play vital roles in endocrine function as 
well as the central and peripheral nervous system. Serotonin is synthesized from the essential 
amino acid tryptophan, absorbed through the diet.  The rate-limiting step, hydroxylation using 
tetrahydrobiopterin as a cofactor, is performed by tryptophan hydroxylase (TPH), which is 
encoded by two genes in mammals (TPH1 and TPH2).  5-hydroxytryptophan is then 
decarboxylated to 5-HT by the non-specific aromatic amino acid (dopa) decarboxylase.  
Degradation is mediated primarily by the monoamine oxidases genes (MAOA and MAOB).  In 
the central nervous system (CNS), serotonin is synthesized and released by the neurons of the 
raphé nuclei.  
! #!
Serotonin is cleared from the extracellular space by the serotonin transporter (SERT; 
Slc6a4), as well as organic cation transporter 3 (Oct3; Slc22a3) (Baganz et al., 2008).  The two 
transporters are distinct in that SERT has high affinity, while Oct3 has relatively low affinity.  In 
adulthood, CNS expression of SERT is limited to the 5-HT synthesizing neurons of the raphé 
nuclei, most markedly in the axonal projections, allowing the transmitter to be re-released 
following vesicular packaging.  The serotonin transporter is of great interest particularly for its 
role in mood and anxiety disorders: selective serotonin reuptake inhibitors (SSRIs) and most 
tricyclic antidepressants (TCA) are inhibitors of SERT, and serve as frontline treatments for 
depression and anxiety. 
Serotonin signaling is mediated by a large variety of receptors; 17-18 genes (in humans, 
the 5-HT5B receptor is a pseudogene) encode dozens of isoforms of 5-HT receptors (Bockaert et 
al., 2010).  All members of the serotonin receptor family, with the exception of the 5-HT3 
receptors, are G protein-coupled.  As this thesis is primarily concerned with several specific 
receptors, namely the 5-HT1 receptor subgroup, the reader is referred elsewhere for more 
thorough review of the signaling of the remaining 5-HT receptors (Raymond et al., 2001; 
Bockaert et al., 2004; Costall and Naylor, 2004; Lanfumey and Hamon, 2004; Leysen, 2004; 
Nelson, 2004; Thomas and Hagan, 2004; Woolley et al., 2004).   
The 5-HT1A receptor is expressed in most brain regions, with particularly high expression 
in the cortex, hippocampus, amygdala, and raphé nuclei, on excitatory and inhibitory neurons. In 
the raphé nuclei, the 5-HT1A receptor is located somatodendritically on serotonergic neurons; 
expression in axons/terminals has not been reported.  The receptor is coupled to G!i/o proteins 
[with G!i3 being the dominant form in the rostral raphé (Mannoury la Cour et al., 2006)] through 
which it acts to inhibit the cAMP-dependent kinase cascade and to open G protein-coupled 
! $!
inwardly rectifying potassium channels.  5-HT1B has a very similar signaling mechanism, 
coupling to Gi/o to inhibit cAMP dependent pathways, although activation of adenylate cyclase 
and phospholipase C have also been reported, in transfected cell lines (Lanfumey and Hamon, 
2004).  5-HT1B expression is confined to axons and terminals, where it serves as an autoreceptor 
(on serotonergic projections) or a heteroreceptor, presynaptically modulating neurotransmitter 
release.   
 
      
Figure 1.1 – Schematic representation of serotonergic function (reproduced from Albert, 2011).  
5-HT is synthesized from tryptophan by the enzymes TPH2 and aromatic amine decarboxylase 
(AADC), and packaged into vesicles by Vmat2; reuptake is mediated by 5-HTT (SERT).  




Serotonin plays numerous roles in the central, peripheral, and enteric nervous systems.  In 
the peripheral nervous system, serotonin does not appear to be released by synaptic mechanisms; 
rather, peripheral neurons expressing 5-HT receptors are activated by serotonin released from 
mast cells and platelets (Sommer, 2004), and may have a role in mediating inflammatory pain.  
In the enteric nervous system, serotonin mediates gastrointestinal motility and secretion 
(Gershon, 2004), while serotonergic projections to the spinal cord are involved in several 
processes, including nociception, reflex modulation, and locomotor rhythm production (Shapiro, 
1997; Schmidt and Jordan, 2000). This review, however, will focus on the role of serotonin in 
the forebrain. 
 
Figure 1.2: Schematic representation of the human serotonergic system.  Reproduced from Tork, 
1990. 
! &!
1.1 – The central serotonergic system 
 All serotonergic projections in the CNS arise from the brainstem raphé nuclei, located in 
caudal midbrain extending into the medulla along the midline.  The raphé region of the brain has 
been anatomically classified into two subgroups, rostral and caudal (figure 1.2), containing nine 
specific nuclei (B1-B9).  Projections from the raphé extend from the rostral group to the 
forebrain, and from the caudal group to the spinal cord, with a subset of projections from both 
groups targeting brainstem regions and the cerebellum (Tork, 1990).  Although the raphé nuclei 
are the home of CNS serotonergic neurons, they contain many non-serotonergic cells, including 
glutamatergic, GABAergic, and peptidergic neurons.  The proportion of raphé neurons 
expressing serotonergic markers varies greatly between the different nuclei, from nearly all in the 
ventral intra-fascicular area of the dorsal raphé, to only 10-20% in paramedian/lateral regions of 
the median raphé (Hornung, 2010). 
 The rostral raphé nuclei include the dorsal raphé (DRN), median raphé (MnR), and 
caudal linear (CLi) nuclei.  The DRN represents the largest collection of serotonergic neurons in 
the brain, approximately one third of the total (Hornung, 2010), and is principally located ventral 
to the cerebral aqueduct and periaqueductal grey.  The DRN may be further subdivided into 
subnuclei: ventromedial (vmDR), dorsomedial (dmDR), and lateral wings (lwDR) (Calizo et al., 
2011).  The MRN is contiguous dorsally with the intra-fascicular vmDR, lying between the 
medial longitudinal fasciculus and the ventral tegmentum.  The midline MRN contains a high 
concentration of serotonergic neurons, flanked on either side by the paramedian groups, and 
further laterally with scattered 5-HT neurons in the pontomesencephalic reticular formation.  The 
CLi extends rostrally and ventrally from the DRN, and contains dopaminergic as well as 
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serotonergic neurons.  The connectivity of the rostral raphé will be discussed in detail in section 
1.1.1. 
 The caudal raphé nuclei consist of the raphé magnus (RMg), raphé obscurus (ROb), and 
raphé pallidus (RPa). Projections of the caudal group lead mainly to the caudal brainstem and 
spinal cord.  Specific targets include the cranial motor nuclei, and the dorsal and ventral horn 
motor nuclei.  Both somatic and autonomic motor neurons are targeted, with the latter frequently 
showing neuropeptide expression.  Afferents to the caudal raphé arise from the hypothalamus, 
periaqueductal gray, central nucleus of the amygdala, and the bed nucleus of the stria terminalis. 
  
 
1.1.1 – Connectivity of the Rostral Raphé Nuclei 
 The DRN and MRN provide the vast majority of serotonergic innervation to the forebrain, 
and as such, are considered most relevant in studying the relationship between serotonin and 
emotional behavior.  Serotonergic projections appear in two distinct types: course fibers, with 
large bulbous varicosities, and fine fibers, with small fusiform or granular varicosities (Kosofsky 
and Molliver, 1987); figure 1.3.  The fine axons generally lack any form of post-synaptic 
specialization, suggesting a paracrine form of transmission, while the course axons often have 
associated post-synaptic densities.  In general, fine axons arise from the DRN, and course axons 
arise from the MRN, and are hence termed type D and type M fibers respectively.  The fine 
fibers are selectively vulnerable to substituted-amphetamine toxins (e.g., 3,4-
methylenedioxymethamphetamine (MDMA), para-chloroamphetamine (PCA)), which can be 
prevented by serotonin transporter blockade (Fuller and Snoddy, 1986).  In the nucleus 
accumbens, fine axons express SERT quite widely, while coarse varicose axons are largely 
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devoid of SERT immunoreactivity (Brown and Molliver, 2000); likewise, fibers that lack SERT 
have been reported in prefrontal cortex, hippocampus, and septum (Amilhon et al., 2010).  
Although it is not firmly established to what extent M type fibers lack SERT throughout the 
brain, they are certainly far less susceptible to SERT-mediated toxicity than D type fibers.  These 
findings suggest that SERT blockade targets a subset of 5-HT projections, chiefly arising from 
the DRN, implicating the DRN as the primary target of SSRIs (Hensler, 2006). 
 
Figure 1.3 - 5-HT immunoreactive fibers in the parietal cortex.  Filled arrow indicates an M type 
fiber with large, bulbous varicosities; open arrow denotes a D type fiber.  Reproduced from 
(Kosofsky and Molliver, 1987). 
  
The cerebral cortex receives innervation from both the MRN and DRN, with the DRN 
projections predominating.  Serotonergic density is highest in the frontal cortex, with all layers 
receiving both fine and coarse projections.  Fine projections in other cortical regions also target 
all layers, while type M fibers target mainly layers II and III (Hensler, 2006).   
158 B.E. KOSOFSKY AND M.E. MOLLIVER 
Fig. 2. Seroton  (5-HT) immunoreactive axons in cerebral c rtex of 
rat. A Dorsal frontal cortex. Note the high density of axons with very 
small, granular or fusiform varicosities; these are type D fibers. B: 
Posterior parietal cortex. Note the heterogeneity of fiber morphology. 
One prominent type M fiber (solid arrow) is adjacent to a type D (open 
arrow) fiber. C: Dentate gyrus of the hippocampus (granule cell layer
above; hilus below). Note the band of fibers subjacent to the granule 
cell layer, all of which have large spherical varicosities; these are type 
M fibers. 2A-C:bar = 50 pm. 
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The hippocampus receives innervation from both DRN and MRN, with MRN projections 
predominating.  The CA3 region is most intensely targeted, followed by the dentate gyrus (DG), 
and then the CA1 region.  In the DG, D type fibers dominate in the hilar region and molecular 
layer, while M type fibers are concentrated in the granule cell layer (Hensler, 2006).  The CA3 
receives a high density of both fiber types to the stratum radiatum and oriens.  The entorhinal 
cortex also receives dense serotonergic innervation from both the DRN and MRN, with D type 
fibers dominating in layer I and M type fibers dominating in layer III (Kosofsky and Molliver, 
1987).   
The striatum is mainly innervated by D type fibers, with the nucleus accumbens caudal 
shell receiving M type fibers (Brown and Molliver, 2000).  The shell is more densely targeted 
than the core, particularly in the caudal regions.  Only in the caudal shell do serotonergic 
projections survive PCA toxicity, and these fibers lack SERT (Brown and Molliver, 2000). 
The serotonergic innervation of the amygdala is quite complex.  The rostral and medial 
subregions of the basal amygdaloid nucleus receive especially dense serotonergic innervation, as 
does the lateral nucleus (Steinbusch, 1981). In general, D type fibers predominate, with sporadic 
M type projections found mainly in the central, lateral, and basal nuclei (Sadikot and Parent, 
1990).  The bed nucleus of the stria terminalis receives dense serotonergic innervation in the 
lateral dorsal and lateral ventral subnuclei (Freedman and Shi, 2001). 
The proportion of 5-HT immunoreactive axon terminals that form synapses varies 
considerably across the regions of the brain (Descarries et al., 2010).  In rat cortical regions, it 
ranges from 20-40%, tending to be lower in frontal and prefrontal areas and higher in parietal 
and occipital cortex.  In the hippocampus, about 20% of serotonergic terminals have associated 
post-synaptic structures.  The basal forebrain and diencephalon show even greater variability: 
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76% of the axon terminals in the basolateral amygdala are immunoreactive, 46% in the diagonal 
band of Broca, 6-13% in the striatum, and roughly 50% in the thalamus and hypothalamus (id.).   
 Afferents to the DRN come from a number of sources including both cortical and 
subcortical regions; most of these have been determined using anterograde and retrograde tracers, 
so the neurochemical identity of the projections and their targeted raphé neurons are not known 
in many cases.  Nonetheless, these studies demonstrated that the orbital cortex shows high 
connectivity to the DRN, with lateral regions of the orbital cortex preferentially projecting to the 
vmDR and lwDR, medial regions to the lwDR, and ventral regions to rostral dmDR (Peyron et 
al., 1998).  The anterior cingulate is also a large source of fibers to the DRN, particularly to the 
rostral area and lateral wings.  Infralimbic cortex preferentially targets the lwDR and dmDR.  
Additional cortical inputs to the DRN arise from the elsewhere in the frontal lobe and insula.   
Most regions of the basal forebrain provide substantial input to the DRN (Peyron et al., 
1998).  Most prominent are the ventral and posterior bed nuclei, which display some preference 
to the dorsal subregion of the DRN.  The ventral pallidum, substantia innominata, claustrum, and 
septal nuclei also provide significant input.  The nucleus accumbens core and shell provide some 
input, with preference to the lwDR.  Amygdala afferents to the DRN arise mainly from the 
central and medial nuclei (id.). From the hypothalamus, the preoptic areas provide extensive 
innervation to all regions of the DRN.  In the anterior hypothalamus, the dorsomedial nucleus, 
and dorsal, lateral, and posterior hypothalamic areas have major projections to the DRN.  All the 
nuclei of the DRN receive extensive projections from the lateral habenula (Peyron et al., 1998) . 
 In general, the general pattern of afferent projections to the MRN is similar to that of the 
DRN, with some exceptions.  From the cortex, cingulate projections are most prominent, with 
fewer projections coming from the lateral and ventrolateral orbital cortex (Behzadi et al., 1990).  
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In the basal forebrain, moderate innervation from the lateral septum is observed, as well as the 
ventral pallidum, bed nuclei of the stria terminalis, and the preoptic area.  Amygdalar inputs to 
the MRN are, in contrast to the DRN, largely from the anterior nucleus.  The MRN also receives 
extensive inputs from the ventral tegmental area and substantia nigra.  Notably, the MRN has a 
number of afferents from the DRN and periaqueductal gray, as well as the raphé magnus and 
obscurus (id.).   
 
1.2 – The serotonin system in development 
  Although serotonin is most well known for its role as a neurotransmitter, 5-HT signaling 
is intricately involved in the development of the brain. Key neurodevelopmental processes 
including proliferation, differentiation, migration, dendritic growth, synaptogenesis, and pruning 
(Sodhi and Sanders-Bush, 2004) have been shown to involve serotonergic signaling.   
1.2.1 – Ontogeny of the serotonin system 
Serotonergic neurons arise from two populations of progenitors: a rostral group giving 
rise to the DRN, MRN, CLiR, and ventral lateral cell group; and a caudal group giving rise to the 
raphé pallidus and obscurus, with both groups contributing to the raphé magnus (Lidov and 
Molliver, 1982; Rubenstein, 1998).  In the rat, serotonin is detectable by E12-E14, and the 
essential layout of the raphé nuclei is complete by birth (Lidov and Molliver, 1982).  
Serotonergic neurite outgrowth begins shortly after the expression of SERT, at around E13 
(Narboux-Nême et al., 2008; Daubert and Condron, 2010), and continues well into postnatal 
development.   
 Serotonergic neurons arise caudal to the midbrain-hindbrain organizer, in rhombomeres 
r1-r3 and r5-r7 (Alenina et al., 2006), representing the rostral and caudal developmental groups.  
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Early on, Phox2b blocks serotonergic cell fate, but is silenced by Nkx2.2 in precursors, except 
for in r4 where it remains expressed.  In the mouse,markers of serotonergic lineage (e.g., SERT, 
Tph2) are expressed by E11, induced by a transcriptional network including Pet1, Lmx1b, 
Nkx2.2, Mash1, Gata2, and Gata3 (Alenina et al., 2006).  Nkx2.2 lies downstream of both Pet1 
and Lmx1b. In the absence of either Nkx2.2 or Lmx1b, using gene knockouts, serotonergic 
neuron formation is completely prevented (Cheng et al., 2003), while the Pet1 knockout mouse 
retains approximately 30% of the normal adult serotonergic population (Kiyasova et al., 2011). 
 Serotonin appears early in embryonic development, and is present in greater-than-adult 
levels throughout a large portion of postnatal development.  Moreover, the expression of many 
serotonergic receptors appears within a similar time frame.  The 5-HT1A receptor is detected at 
E12 in rat brain, and undergoes a massive peak in expression around E15 (Hillion et al., 1993), 
with a comparable transient overexpression seen in the human fetus at 18-20 weeks gestation 
(Bar-Peled et al., 1991).  SERT expression is much higher in development than in adulthood, 
with expression in non-serotonergic cells occurring, most notably in thalamocortical projections 
(Lebrand et al., 1996; Narboux-Nême et al., 2008; Daws and Gould, 2011).  SERT binding is 
first detected at E12 in mice, and by E18 it is present in all brain regions where 5-HT is detected 
(Brüning et al., 1997).  Expression in the raphé is highest at birth and during early postnatal 
development, declining to adult levels by 4-5 weeks of age in both rat and mouse (Galineau et al., 
2004; Sidor et al., 2010).  In contrast, SERT expression in amygdala, hypothalamus, and 
somatosensory cortex increases after birth, peaking between P5 and P20 (Galineau et al., 2004). 
The initial infiltration of serotonergic fibers into their target brain regions occurs during 
late embryonic periods, however adult patterns of innervation may not be achieved until 
adolescence (D'Amato et al., 1987; Vu and Tork, 1992).   In the rat, 5-HT-immunoreactive 
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ascending projections are first observed at E13, reaching the hypothalamus by E15, and the 
frontal cortex by E17 (Wallace and Lauder, 1983).  Even beyond this time, however, many axons 
appear to have minimal arborization within the projection regions, and infrequent ramifications 
between regions that are a hallmark of the adult pattern of innervation.  An additional distinction 
from the adult pattern is the bilaminar distribution of fibers on either side of the cortical plate, 
with occasional fine fibers penetrating from each side.   
In a detailed study of serotonergic cortical projections in postnatal cat brain, Vu and Törk 
describe the distinct developmental trajectories of the M and D fiber types (Vu and Tork, 1992).  
Fine D-type fibers were observed in newborn kittens, increasing in density during weeks 3-4, and 
peaking at week 8.  At birth they are distributed fairly evenly within the prefrontal cortical layers, 
but develop a clear preference to layers II and III over the following two months.  In contrast, M 
type fibers were only visible a week after birth in the prefrontal cortex, and 2-3 weeks after birth 
in auditory and visual cortex, proliferating most extensively between 3 and 7 weeks postnatal.  In 
contrast to the cortical pattern of development, 5-HT innervation of the basal forebrain primarily 
consists of thick M-type fibers with few varicosities at birth (Dinopoulos et al., 1997).  The 
proportion of varicosities engaged in symmetrical synapses in the basal forebrain varies across 
the developmental trajectory, from 21% at birth to 43% at P14, then declining to 17% at P21 
before again increasing to adult levels (46%).  The total number of varicosities also fluctuates, 
peaking at P21 before declining to adult levels.  These findings demonstrate that while 
serotonergic projections are present at birth, extensive remodeling occurs during the postnatal 




1.2.2 – Trophic actions of serotonin during development 
Serotonin exerts a number of trophic effects during development.  Of note, high 
concentrations of 5-HT are found in the growth cone of developing raphé projections (Wallace 
and Lauder, 1983).  Injection of 5-HT into the albumin of chicken eggs leads to an increase in 5-
HT content and brain mass, affecting brain protein content but not DNA content (Ahmad and 
Zamenhof, 1978).  Explants of visual cortex from newborn rats show increased synaptic density 
and glial proliferation when cultured with 5-HT (Chubakov et al., 1986).  Depletion of 5-HT in 
neonatal rats using 5,7-dihydroxytrymptamine or PCA has been observed to cause permanent 
reductions in dendritic spine density in the dentate gyrus (Yan et al., 1997), possibly via 5-HT1A 
receptor action on glia (Wilson et al., 1998).  In explant cultures of the hippocampus, co-culture 
with raphé tissue leads to an increased rate of growth, and accelerated development (but reduced 
frequency) of spontaneous activity (Chubakov et al., 1993).  The role of the 5-HT1A receptor in 
trophic signaling is further underscored by the recent observation that it can form a 
heteroreceptor complex with FGF-receptor 1, leading to synergistic transactivation of Erk1/2 
with FGF2 and increased neurite density in primary hippocampal culture (Borroto-Escuela et al., 
2011).  Interestingly, transplants of fetal raphé into adult animals develop hippocampal 
projections, and transplants of fetal hippocampus into adult mice are deeply innervated by host 
animal 5-HT projections within a month (Azmitia et al., 1981); this suggests that serotonergic 
innervation has the potential to be dynamically regulated throughout the lifespan, by both 
serotonergic and target tissue.   
The trophic effects of 5-HT1A receptor activation also extend to regulation of apoptosis.  
In serum-deprived primary neural cultures, the agonist 8OH-DPAT reduces the proportion of 
! "%!
apoptotic cells (Ahlemeyer and Krieglstein, 1997; Ahlemeyer et al., 1999).  Interestingly, 5-HT1A 
is upregulated by nutrient deprivation, most prominently in cells showing early apoptotic 
changes (Singh et al., 1996); thus under conditions of cellular stress, neurons may express 
increased 5-HT1A in order to more sensitively receive anti-apoptotic serotonergic signals.  Other 
conditions which drive 5-HT1A expression include adrenalectomy (Huang and Azmitia, 1999) 
and antagonist treatment (Nishi and Azmitia, 1999), underscoring the dynamic regulation of this 
receptor.  
Of note for the current work, serotonin has been found to regulate survival and neurite 
outgrowth of serotonergic neurons themselves.  In cultures of E14 rostral rhomboencephalon, 
serotonergic neurons showed increased proliferation, but inhibited neurite outgrowth, in response 
to serotonin treatment (Liu and Lauder, 1991).  In contrast, 5-HT-immunoreactive neurons from 
E14 raphé and hippocampus co-culture treated with 5-HT for 4 days showed not only a similar 
blunted arborization, but also increased autapse formation and reduced survival (Whitaker-
Azmitia and Azmitia, 1986b).  Explants of medial brainstem from E13 mice show a major 
elevation of Tph activity over two weeks in culture; when the rostral and caudal cell groups are 
cultured as separate explants, the Tph increase is greater, suggesting that collateral innervation 
between raphé cell groups may provide an autoinhibitory growth signal (Jonakait et al., 1988).  
Further supporting that hypothesis, MAO inhibition curbed the increase in Tph activity, but not 
in the presence of methiothepin (a non-specific 5-HT1A antagonist).   
In both 5-HT1A and 5-HT1B knockouts, the number of serotonergic neurons is greatly 
enhanced in primary cultures, while SERT KO leads to a reduced number of neurons in culture 
and in vivo (Lira et al., 2003b; Rumajogee et al., 2004), suggesting that in early development 5-
HT1 receptors provide a homeostatic anti-proliferative signal.  In 5-HTergic neuron containing-
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cultures, BDNF also exerts a potent serotonin-dependent stimulatory effect on neurite growth; 
this effect was greatly enhanced in the 5-HT1A receptor KO, while it was somewhat impaired in 
the SERT KO (Rumajogee et al., 2004).  
A number of studies have identified a bidirectional signaling loop between 5-HT and glia 
during development.  Primary glial cell cultures express a variety of serotonin receptors, 
including all 5-HT1 and 5-HT2 subtypes (Hirst et al., 1998).  In neonatal astrocyte culture, 5-HT 
stimulates release of a factor that promotes the growth of serotonergic neurons (as measured by 
5-HT uptake), via the 5-HT1A receptor, but becomes toxic at high concentrations (Whitaker-
Azmitia and Azmitia, 1989).  This factor, subsequently identified as S100", has trophic effects 
modulated by BDNF: in isolation, it promotes dendrite extension, and when applied in 
combination with BDNF it promotes somal expansion (Nishi et al., 2000).  Prenatal alcohol 
exposure has been shown to reduce the number of both serotonergic neurons and S100"-positive 
astrocytes, an effect which can be blocked by co-administration of a 5-HT1A agonist to the 
mother (Eriksen et al., 2002; Tajuddin et al., 2003).  Exogenous S100" administration has also 
been shown to reduce ethanol toxicity in serotonergic neurons in vitro (Eriksen and Druse, 2001).  
In neurons, S100" exerts its antiapoptotic effects via the receptor for advanced glycosylation end 
products (RAGE), and stimulation of NF-#B signaling (Villarreal et al., 2011).  Stimulation of 
astroglia via 5-HT2 receptors has also been reported to induce GDNF expression (Hisaoka et al., 
2004; Tsuchioka et al., 2008).  Of clinical concern, reduced serum S100" levels have been found 
in umbilical cord serum from neonates whose mothers were being treated with SSRIs, even after 
controlling for mood (Pawluski et al., 2009). 
The 5-HT1B autoreceptor also has a key role in development, which has been studied 
mainly in relation to thalamocortical afferents.  During development, thalamic sensory neurons 
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are among the cells that adopt a ‘pseudo-serotonergic’ phenotype, expressing both SERT and 
vesicular monoamine transporter 2 (Vmat2); they capture and release serotonin synaptically, but 
cannot synthesize it (Gaspar et al., 2003).  These neurons also express the 5-HT1B receptor as a 
presynaptic autoreceptor, which appears to have significant role in guiding their cortical 
projections.  In primary culture of E15 thalamus, treatment with 5-HT or the 5-HT1B agonist 
CGS-122066A enhances neurite outgrowth (Lotto et al., 1999).   In mice lacking SERT or 
MAOA, the patterning of thalamocortical projections to primary visual and somatosensory barrel 
field cortex is partially disrupted, and heavily disrupted in double KO mice (Salichon et al., 
2001).  Interestingly, the additional deletion of the 5-HT1B receptor gene leads to a restoration of 
near-normal patterning.  Evidence investigating these findings suggests that 5-HT1B activation 
does not influence the initial infiltration of the cortex with thalamic afferents, but rather the 
production and retraction of collaterals during the early postnatal period (Rebsam et al., 2002).   
In conclusion, these findings suggest that the developmental role of serotonin is quite 
involved.  In projection regions, serotonin appears to stimulate differentiation and 
synaptogenesis in neurons, and proliferation in glia.  Among serotonergic neurons, serotonin 
appears to have a more nuanced role, stimulating proliferation in early embryonic development 
but providing feedback inhibition to neurite outgrowth, and even reduced cell survival, through 
both direct and indirect mechanisms. 
 
1.3 – Effects of developmental manipulation of the serotonin system 
 Given the many roles of serotonin in neurodevelopmental processes, it is unsurprising 
that developmental manipulations of the serotonergic system exert significant effects on anatomy, 
physiology, and behavior.  While many studies in rodents have used pharmacological and 
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genetic manipulation of the serotonergic system to probe its developmental role in adult 
behavioral phenotypes, one model that has received particular attention has been postnatal 
treatment with inhibitors of the serotonin transporter, including both the selective serotonin 
reuptake inhibitors (SSRIs) and many tricyclic antidepressants.   
The treatment of neonatal rat pups during the first three weeks of life with the tricyclic 
antidepressant clomipramine results in a depression-like adult phenotype in adulthood.  This 
behavioral phenotype includes a constellation of behaviors thought to be regulated by serotonin, 
including reductions in novelty exploration and social interaction (Rodriguez Echandia and 
Broitman, 1983b), increased ethanol preference (Hilakivi et al., 1984), suppressed acquisition of 
active avoidance (Drago et al., 1985), reduced intraspecific aggression (Vogel et al., 1988), 
reduced male sexual behavior (Neill et al., 1990), and increased immobility in the forced-swim 
test (Velazquez-Moctezuma and Diaz Ruiz, 1992).  However, clomipramine targets both the 
serotonergic and the norepinephreniergic systems and although it has significantly greater 
affinity for the serotonin transporter than the norepinephrine transporter, the relative contribution 
of these targets to the adult phenotype was not clear.   
More recently, postnatal treatment with SSRIs has been used to more precisely identify 
the contribution of developmental perturbations of serotonin on adult behavior.  This research 
was partially stimulated by the observation that SERT knockout mice display behavioral 
alterations that are largely opposite to the actions of SSRIs in adult mice, including higher 
immobility in the forced-swim test, increased novelty-suppressed feeding, increased latency to 
escape shock, and increased immobility in the tail suspension test (Lira et al., 2003a).  
Surprisingly, many aspects of this behavioral phenotype are replicated in mice treated with 
fluoxetine from P4-P21 (Ansorge et al., 2004), suggesting that the effects of SERT knockout are 
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due particularly to its absence during this critical developmental window.  Several other groups 
have also reported altered affective behavior using similar paradigms of rodent postnatal SSRI 
treatment, and have also described alterations in REM sleep, aggression and sexual behavior 
(Manhaes de Castro et al., 2001; Maciag et al., 2006b; Lisboa et al., 2007; Popa et al., 2008; 
Karpova et al., 2009).  In sum, the phenotype of adults treated postnatally with SSRIs appears to 
be one of ‘behavioral inhibition’: reduced exploratory drive/increased novelty avoidance, 
impaired shock escape, and reduced sexual and aggressive behavior.   
Behavioral data have accumulated to suggest that this phenotype is highly dependent on 
the time of postnatal treatment.  A similar course of fluoxetine treatment in adult mice exerts no 
lasting effect (tested 10 weeks after treatment cessation) on exploratory activity, novelty 
avoidance, or shock avoidance (Ansorge et al., 2008).  Likewise, fluoxetine treatment from P21 
to P49 did not produce any alteration in exploratory or anxiety measures in mice tested at ten 
weeks of age (Norcross et al., 2008).  Ongoing work in our lab has further narrowed the 
developmental critical period: fluoxetine treatment of mice from P2 – P11 replicates the 
phenotype of P4 – P21 treatment, while treatment from P12 – P21 does not (unpublished data).  
Several studies have attempted to elucidate the biological mechanisms associated with 
the postnatal-SSRI behavioral phenotype.  Maciag and colleagues report that P8-P21 citalopram 
treatment leads to reductions in adult levels of tryptophan hydroxylase immunoreactivity within 
the raphé, as well as reduced SERT immunoreactivity in the cortex of rats (Maciag et al., 2006b).  
Further work from the same group reports altered morphology of SERT-immunoreactive fibers 
in the PFC and hippocampus, as well as abnormal myelination and oligodendrocyte dysfunction 
in the corpus collosum (Simpson et al., 2011).  In contrast, male rats treated from P2 – P5 with 
fluoxetine or the norepinephrine reuptake inhibitor reboxetine show elevated cortical SERT 
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levels at P90, as measured by [3H]-paroxetine binding assay (Bock et al., 2005).  Postnatal 
fluoxetine (P4 – P21) has also been shown to lead to a lasting increase in BDNF IV mRNA, and 
reduced TrkB.T1 mRNA, in mouse hippocampus (Karpova et al 2009).  
Also of potential relevance are studies of the neurochemical and electrophysiological 
effects of postnatal clomipramine treatment.  Treatment from P8 – P21 led to reduced 
concentrations of both serotonin and norepinephrine in homogenates prepared from frontal 
cortex, hippocampus, brainstem, septum, and hypothalamus (Vijayakumar and Meti, 1999).  In 
contrast, a similar study utilizing treatment from P2 to P14 found reduced serotonin 
concentration in the hypothalamus, but not in frontal cortex, amygdala, or rostral brainstem 
(Feenstra et al., 1996).   
A reduction in the in vivo firing rate of electrophysiologically-identified serotonergic 
neurons in the raphé has been reported in adult postnatally (P8 – P21) clomipramine-treated rats 
(Kinney et al., 1997).  In our lab, we have obtained similar data showing a reduction in firing 
rates of DRN 5-HTergic cells in anesthetized adult mice following postnatal fluoxetine treatment 
(unpublished data; figure 1.4); this finding closely resembles reductions in firing rate previously 
described in SERT knockout mice (Lira et al., 2003a). The source of this firing rate change is 
unknown, and many potential mechanisms can be envisioned. For example, altered balance of 
excitatory/inhibitory projections to 5-HT neurons, changes in the receptor or associated signaling 
pathways that regulate autoinhibitory feedback sensitivity (5-HT1A, Gi3, GIRK, RGS family 
members, GAPs, GEFs, etc), changes in the receptors or post-receptor signaling pathways of 
other transmitters, altered complements of ion channels that regulate excitability, etc. 
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Figure 1.4 – Reduced basal firing rate of serotonergic neurons of the dorsal raphé following 
postnatal fluoxetine treatment.  Top: mean firing rate of 5-HT neurons in SERT wildtype and 
heterozygote mice, treated P4-P21 with either saline or fluoxetine.  Bottom: representative 
recordings from vehicle (upper) or fluoxetine (lower) treated animals.  Unpublished data. 
 
In parallel with these findings demonstrating the influence of developmental serotonin 
transporter function on affective behavior in adulthood, increased anxiety-like behavior is seen in 
5-HT1A knockouts, and this phenotype can be rescued by forebrain expression of the receptor 
during development (Gross et al., 2002).  What is more, in the same way that postnatal SSRI 
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treatment can largely replicate the SERT knockout phenotype (Ansorge et al., 2004), the 5-
HT1A receptor knockout anxiety phenotype can be reproduced by postnatal treatment (P13-P34) 
with a 5-HT1A antagonist: WAY-100635 (Lo Iacono and Gross, 2008).  Interestingly, postnatal 
treatment (P5-P33) of SERT knockouts with WAY-100635 reverses depression-like behavior 
and REM sleep abnormalities (Alexandre et al., 2006); this suggests that impaired serotonin 
clearance leading to hyperactivation of 5-HT1A is critical in the adult phenotype.  
The serotonergic system also interacts developmentally with other neuromodulatory 
systems.  5,7-dihydroxytryptamine lesion of the raphé on P3 and P5 leads to an increase in 
dopaminergic fibers in the prefrontal cortex (Bolte Taylor et al., 1998).  In contrast, lesion of the 
dopaminergic system by 6-hydroxydopamine at P5 leads to a decrease in serotonergic fibers in 
the PFC (Cunningham et al., 2005).  Furthermore, treatment with the norepinephrine reuptake 
inhibitor reboxetine from P2-P5 leads to increased SERT binding in frontal cortex, and 5-HT1A 
receptor agonists have been reported to stimulate the dendritic arborization of cholinergic 







1.4– Serotonin in depression 
 
 Blockade of monoamine transporters or degrading enzymes has been the mainstay of 
depression pharmacotherapy for more than 50 years.  SSRIs are now first line treatment for not 
only depression, but also many anxiety disorders.  Yet, despite the empirical efficacy of these 
drugs, our understanding of the biological mechanisms mediating these effects are still 
rudimentary.  It is quite certain that prevention of serotonin reuptake is the initial, therapeutically 
relevant action, but what follows downstream to actually improve mood and anxiety symptoms is 
unclear.  This lack of mechanistic knowledge has severely hampered development of novel 
antidepressant strategies, which are direly needed: response rates to first time SSRI treatment are 
estimated at 50-60%, and treatment-resistant depression is disturbingly common (Kroenke et al., 
2001; Ruhé et al., 2006).   
Despite the fact that near-total serotonin transporter blockade occurs rapidly following 
SSRI administration, clinical response occurs gradually over a period of approximately six 
weeks, as shown in figure 1.5 (Taylor et al., 2006).  The discrepancy between acute drug action 
and delayed therapeutic effect implies that a long-term, adaptive process responsible for 
therapeutic efficacy must be occurring secondary to the blockade of transporter.  On the other 
hand, acute tryptophan depletion leads to a transient recurrence of depression symptoms in a 
majority of remitted depressed subjects, whether still on SSRI or medication free (Neumeister, 
2003).  This apparent inconsistency suggests that both long-term adaptive changes and acute 
maintenance of serotonin levels are required for SSRI response. 
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Figure 1.5 – Meta-analysis of SSRI treatment response in depression. A - Best fit model 
(logarithmic). B – Weighted mean difference between SSRI and placebo groups on the Hamilton 
Depression Rating Scale (left) and Montgomery-Asberg Rating Scale (right).  (Reproduced from 
Taylor et al., 2006, Archives of General Psychiatry) 
 
  
1.4.1 – The autoreceptor desensitization hypothesis 
This ‘therapeutic lag’ has been the topic of much research, spawning many hypotheses.  
One of the more prominent of these is the autoreceptor desensitization hypothesis, which also 
accounts for the effects of tryptophan depletion.  According to this model, the onset of SSRI 
treatment leads to a rapid increase in extracellular serotonin in the raphé, activating 
somatodendritic 5-HT1A receptors and thus decreasing firing rate.  Over the course of 1-3 weeks, 
these autoreceptors are desensitized, and the firing rate of 5-HT neurons returns to baseline 
levels.  Extensive data characterizing this phenomenon has been reviewed elsewhere (Blier et al., 
1998; Blier and Abbott, 2001; Hensler, 2003; Albert et al., 2011), so I will focus on more recent 
work with greater relevance to the questions posed here. 
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 Autoreceptor desensitization has generally not been associated with any actual change in 
the expression of the 5-HT1A receptor.  However, the vast majority of studies have not been 
conducted in rodent models of depression.  In mice selectively bred for immobility in the tail-
suspension test (TST), there are alterations in the forced-swim test and in sleep architecture 
suggesting that they may be a useful model of depression (El Yacoubi et al., 2003). In these mice, 
there is a significant upregulation of 5-HT1A receptor binding throughout the brain, particularly 
in the dorsal raphé (Naudon et al., 2002a).  This upregulation is normalized by three week 
treatment with fluoxetine, which also decreases immobility time in the TST.  Likewise, isolation 
housing of mice leads to increased 5-HT1A receptor binding throughout the brain, which is 
countered by citalopram treatment (Günther et al., 2008).  In another study modeling HPA-axis 
associated depression, three weeks of fluoxetine yielded a much greater desensitization of 5-
HT1A autoreceptors in mice that were chronically treated with corticosterone (Rainer et al., 2011).  
Based on these data, the hypothesis emerges that elevated 5-HT1A binding may be a feature of 
certain animal models of depression, and that antidepressants perhaps only cause a reduction in 
5-HT1A expression under these pathophysiological conditions. 
Recent studies have investigated whether 5-HT1A desensitization is necessary and 
sufficient for the antidepressant behavioral response.  In transgenic lines expressing the 5-HT1A 
receptor under raphé-specific Pet1 control, mice with high autoreceptor expression do not 
respond to chronic fluoxetine treatment on the novelty-suppressed feeding test, while those with 
low autoreceptor expression have a robust response (Richardson-Jones et al., 2010).  However, 
both lines show nearly complete desensitization of 5-HT1A in the agonist-induced hypothermia 
challenge when treated for 35 days with fluoxetine.  Small interfering RNA-mediated 
knockdown of 5-HT1A autoreceptors (performed via fusion of the siRNA to sertraline) reduced 
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immobility in the forced-swim and tail-suspension tests, but had no effect on elevated-plus maze 
anxiety measures (Bortolozzi et al., 2011).  In contrast, lifelong genetic knockdown of 5-HT1A in 
the raphé leads to elevated anxiety, but no change in the FST (Richardson-Jones et al., 2011).   
In a study using chronic microdialysis to assess 5-HT concentration and autoreceptor 
activity, raphé and hippocampal 5-HT levels were found to peak after one week of fluoxetine 
treatment, while autoreceptor desensitization appeared after 3-4 weeks (Popa et al., 2010).  
Notably, reduced anxiety related-behavior in the open field was not seen until week four of 
treatment, and center field entries were correlated with the degree of desensitization, but not with 
dialysate 5-HT levels.  However, this timeline for desensitization, measured as a diminution of 
the WAY-100635-induced 5-HT spike, is not generally in agreement with that seen with 
recording 5-HTergic neuron response to 5-HT1A agonist, which occurs in less than 2 weeks; 
perhaps the use of an antagonist in this study better reflects the influence of desensitization on 
endogenous 5-HT1A feedback.  In total, these studies provide support for the contention that 
desensitization, or reduced expression, is necessary and sufficient for an antidepressant 
behavioral response. 
 There is also a significant body of work investigating 5-HT1A autoreceptor 
desensitization in clinical populations.  In these studies, subjects typically receive an acute 
injection of a 5-HT1A agonist, and hypothalamic responses on temperature and/or endocrine 
secretion are measured; the hypothermic response is believed to depend solely on autoreceptor 
expression, while the endocrine response may reflect both pre- and post-synaptic action.  In 
unmedicated depressed subjects, hypothermic, ACTH, and cortisol responses to agonist 
challenge have variously been reported to be decreased (Lesch et al., 1990a; Lesch et al., 1990b; 
Lesch et al., 1992) and increased (Price et al., 1997; Navines et al., 2006).  Treatment with SSRIs 
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has been shown to reduce hypothermic, ACTH, and cortisol responses in depressed (Navines et 
al., 2007), obsessive-compulsive (Lesch et al., 1991), and control subjects (Lerer et al., 1999).  
Treatment with nortripyline, a trycyclic antidepressant, has also been shown to reduce these 
responses (Rausch et al., 2006) in depressed patients, with the degree of desensitization of the 
hypothermia predicting treatment response.  This finding is similar to the findings of a different 
group who showed that in depressed subjects treated with citalopram, the degree of ACTH and 
cortisol response desensitization correlated significantly with Hamilton Depression scores 
(Navines et al., 2007).   
 
1.4.2 – Imaging of the serotonin system in depression 
 The bulk of our understanding of the pathology of the serotonergic system in major 
depressive disorder comes from neuroimaging studies.  Early studies of 5-HT1A using 
[11C]WAY-100635 reported both decreased (Drevets et al., 1999; Sargent et al., 2000; 
Bhagwagar et al., 2004b) and increased (Parsey et al., 2006d) binding in depression.  However, 
because many studies relied on cerebellar gray matter using the simplified reference tissue model, 
and alterations in 5-HT1A binding have been seen in depressed subjects in the cerebellum 
(discussed in greater detail in chapter 4), it is now clear depression is associated with elevated 
receptor expression in both the raphé and post-synaptic regions (Parsey et al., 2005a; Parsey et 
al., 2010).  Elevated 5-HT1A binding is associated with poor treatment response (Parsey et al., 
2006c), but appears to be a trait marker, i.e., is independent of current mood state (Miller et al., 
2009a).  Subjects who have had recent antidepressant medication show a normalization of 5-
HT1A binding that appears to persist for months or even years, independent of their current 
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emotional state (Parsey et al., 2006a; Parsey et al., 2010).  The timeline of this apparent 
downregulation by SSRIs, and whether it relates to treatment response, is not yet known.  
 PET and SPECT studies of SERT in depressed subjects have had mixed results(Smith 
and Jakobsen, 2009), but the preponderance of evidence suggests a reduction in transporter 
density, most notably in the amygdala and midbrain (Newberg et al., 2005; Parsey et al., 2006e; 
Joensuu et al., 2007; Oquendo et al., 2007; Miller et al., 2008; Reimold et al., 2008).  Reduced 
SERT binding may predict poorer treatment response (Kugaya et al., 2004; Miller et al., 2008).  
Additionally, adults who were abused as children have a global reduction of SERT binding 
(Miller et al., 2009b), as do healthy twins of subjects hospitalized for mood disorder (Frokjaer et 
al., 2009).  Notably, SERT expression may be inversely correlated with anxiety in depressed 
subjects (Reimold et al., 2008).   
 The effect of SSRI treatment on SERT expression is difficult to assess in PET studies, as 
occupancy by the treatment drug will obscure potential alterations.  In animal studies, chronic 
SSRI treatment has generally been found to reduce SERT binding and immunoreactivity (Gobbi 
et al., 1997; Benmansour et al., 1999; Benmansour et al., 2002; Gould et al., 2007; Johnson et al., 
2009; Kovacevic et al., 2010); indeed, SERT downregulation may have a greater influence on 
serotonin clearance than SERT blockade itself (Benmansour et al., 2002).  Notably, levels of 
SERT mRNA appear unchanged by SSRI treatment (Benmansour et al., 1999; Benmansour et al., 
2002; Johnson et al., 2009), suggesting this downregulation is occurring at the translational or 
post-translational level.   
A recent study identified microRNA miR-16 as a potential mechanism.  Fluoxetine 
treatment increased raphé expression of miR-16, and fluoxetine downregulation of [3H]-
paroxetine binding could be blocked by infusion with an anti-miR-16 oligonucleotide (Baudry et 
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al., 2010).  Infusion of the raphé with miR-16 mimicked the effects of fluoxetine treatment on 
SERT binding, as well as preventing behavioral alterations induced by unpredictable chronic 
mild stress.  MicroRNAs are believed to suppress mRNA translation via three mechanisms: 
degradation, sequestration of mRNA in ‘processing bodies’, and/or blocking translation initiation 
at the ribosome (McDaneld, 2009); because no reduction in SERT mRNA has been observed 
following fluoxetine treatment, the miR-16 action is likely occurring via the latter mechanism.   
 
1.4.3 – Genetic polymorphisms of the serotonin system and depression 
 Despite ample evidence of a genetic contribution to depression (e.g., concordance in 
monozygotic vs. dizygotic twins), no unambiguously causative polymorphisms have been 
described.  Rather, a number of common and uncommon variants with small effect size have 
been reported, often with subsequent failed replications.  Improved experimental methodology, 
comprehensive meta-analyses, and greater awareness of gene x environment interactions have 
recently led to more reliable identification of specific polymorphisms that confer susceptibility to 
depression. 
The 5-HTT noncoding sequence is highly polymorphic.  The HTTLPR tandem repeat has 
typically been described as a high-transcribing ‘L’ (16 repeats) and a low transcribing ‘S’ (14 
repeats), although the number of repeats may extend up to 22, giving rise to the ‘XL’ allele 
(Goldman et al., 2010).  An additional A>G single-nucleotide polymorphism in the common L 
allele creates an AP2 transcription factor binding site, which appears to act as a repressor in this 
case, such that the LG allele possesses a similar efficiency to the S allele (Hu et al., 2006).   
Gene association studies have inconsistently found a relationship between these 
polymorphisms and depression vulnerability, with the S and LG alleles conferring risk in 
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conjunction with stressful life events.  Despite many failures to replicate the initial studies, the 
most comprehensive meta-analysis to date finds strong evidence for this gene-environment 
interaction (Karg et al., 2011).  Some studies have also reported an association between the S and 
LG alleles and treatment resistance, although this finding is controversial (Taylor et al., 2010).  
Interestingly, there is no conclusive evidence that these polymorphisms have any effect on SERT 
expression within the adult brain, with most studies reporting no effect (Heinz et al., 2000; 
Jacobsen et al., 2000; Shioe et al., 2003; van Dyck et al., 2004; Parsey et al., 2006b; Oquendo et 
al., 2007; Reimold et al., 2007; Murthy et al., 2010).  It has been speculated that, much like the 
SERT KO mouse, effects of the HTTLPR may arise from altered expression during 
developmental critical periods. 
 A common single-nucleotide polymorphism of the 5-HT1A receptor gene (HTR1A), C-
1019G, disrupts a palindromic promoter sequence for Deaf1 (deformed autoregulatory factor-1) 
and Hes5.  The G allele leads to increased expression of 5-HT1A in the raphé-like RN46A cell 
line (Lemonde et al., 2003), and increased receptor binding in depressed patients (Parsey et al., 
2006a; Parsey et al., 2010).  This variant has also been associated with poorer antidepressant 
treatment response (Lemonde et al., 2004; Kato et al., 2008; Le François et al., 2008; 
Yevtushenko et al., 2010), providing further evidence that 5-HT1A receptor signaling is 





1.5 – Conclusion and rationale 
 Despite the ubiquitous presence of serotonin in the CNS, it arises from a relatively 
miniscule number of cells in the raphé nuclei of the brain stem.  Serotonin’s involvement in a 
wide variety of brain functions, and its central role in our understanding of mood and anxiety 
disorders, make the study of the neurons from which it arises of great importance.   
 While the proximal mechanism of SSRIs, inhibition of serotonin reuptake, is clear, the 
downstream effects are complex and numerous.  During development, manipulation of serotonin 
signaling has profound influences on both behavior and structure.  Postnatal reuptake inhibition 
leads to increases in anxiety- and depression-like behaviors.  Studies of the biological phenotype 
of postnatal SSRI treated mice have been sparse, but report decreases in SERT and TPH 
immunoreactivity, reduced firing rate of 5-HT neurons, and regional reductions in extracellular 
5-HT levels. 
In adulthood, many influences of SERT blockade have been described in projection 
regions, but knowledge about effects on serotonergic neurons themselves is limited.  5-HT1A 
autoreceptor desensitization is perhaps the best-studied phenomenon: inhibitory feedback 
signaling is gradually reduced, leading to a restoration of the acutely suppressed firing rate.  
Transcriptional downregulation of 5-HT1A is less commonly observed, and may be specific to 
depression and its animal models.  Other actions of SSRI treatment on the raphé include the 
suppression of SERT via a post-transcriptional mechanism, and increased serotonin synthesis. 
 We sought to further expand on these findings by studying the effects of SSRI treatment 
on raphé serotonergic neurons, both during development and in adulthood.  In mice treated with 
postnatal fluoxetine, we hypothesized that anatomical alteration of 5-HTergic projections were 
likely, based on the developmental role of 5-HT signaling during this period: elevated 5-HT 
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feedback inhibitory signals, likely mediated by 5-HT1 receptors, were anticipated to prematurely 
halt axonal growth.   
 The prior observation of reduced 5-HT neuron firing rate in vivo led us to seek more 
detailed electrophysiological characterization of PNFLX mice.  We provided PNFLX and 
PNSAL treated mice to collaborators in the laboratory of Sheryl Beck for patch-clamp recording 
of serotonergic neurons, with the aim of identifying whether the reduction in spontaneous firing 
was due to intrinsic alteration of the characteristics of 5-HT neurons, or whether it might be 
attributable to a circuit-level effect (i.e., reduced excitatory or enhanced inhibitory input).   
 Also relating to the in vivo electrophysiology data, and the reports by other groups of 
altered expression of Tph2 and SERT in postnatal SSRI treated mice, we reasoned that these 
persistent changes in serotonergic neuron function might be manifested in the transcriptome.  
Therefore, we utilized the technique of manual cell sorting to achieve a purified population of 
Pet1-positive dorsal raphé neurons for microarray analysis.  Because only one prior study has 
investigated the transcriptome of 5-HT neurons, and utilized FAC sorting of embryonic 
progenitors (Wylie et al., 2010), we also sought to describe more globally the gene expression 
profile of dorsal raphé 5-HT neurons. 
 We have previously reported elevated 5-HT1A binding in unmedicated, but not recently-
medicated, depression.  Coupled with the literature supporting the autoreceptor desensitization 
hypothesis of SSRI function, we performed a PET study of 5-HT1A binding in the raphé, in order 
to test the hypothesis that SSRI treatment would downregulate this receptor, and that this 
downregulation would correlated with treatment response. 
 We also sought to identify other potential alterations in 5-HTergic neurons during adult 
chronic SSRI treatment.  Reasoning that changes in gene expression may correlate with adaptive 
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responses to chronic SSRI treatment (e.g., autoreceptor desensitization), we performed 
microarray analysis, again using the manual cell sorting approach to achieve a purified 
population of Pet1 positive dorsal raphé neurons.  Because postnatal fluoxetine treatment 
blocked, or even reversed, the behavioral response to adult fluoxetine treatment (data presented 
in chapter 5), we performed this experiment in a two-by-two design, allowing us to identify 







Chapter 2:  





2.1 – Labeling of Serotonergic Neurons 
 Several of the methods in this dissertation rely on the specific labeling of serotonergic 
neurons in the mouse brain. In gene targeting of neurons, particularly using a recombinase-
mediated strategy, it is essential not only that expression is specific during the experiment, but 
also throughout development.  For this reason, we chose the gene Pet-1 (a.k.a. FEV, fifth Ewing 
variant), a transcription factor of the ETS family that is highly expressed in serotonergic neurons 
(Scott et al., 2005).  In this driver line (termed ePet-Cre by the authors), a bacterial artificial 
chromosome transgene comprising Cre recombinase preceded by a promoter sequence extending 
40-kb upstream of the Pet-1 coding sequence.  In this study, expression of a floxed reporter 
(ROSAR26R-lacZ) was reported to overlap 100% with tryptophan hydroxylase-2 (TPH2) 
immunoreactivity, and ectopic expression was not found within the brain, spinal cord, or retina.  
For the work presented here, mice from the ePet-Cre line were crossed with ROSAR26R-EYFP 
in order to provide both fluorescent and immunochemical labeling options.   
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Figure 2.1 – Transgenic strategy for labeling of Pet1 neurons. 
 
Pet-1 is intimately involved in specification of serotonergic cell fate (Jacobsen et al., 
2010; Liu et al., 2010), but it has been observed that a serotonergic phenotype is still observed in 
many brainstem neurons in Pet-1 knockout mice (Pearlstein et al., 2011).  Although this clearly 
indicates that Pet-1 is not necessary for all precursor cells to achieve a serotonergic phenotype, it 
does not negate the utility of Pet-1 as a tool for targeting transgene expression to serotonergic 
neurons. 
Alternate strategies for labeling of serotonergic neurons include the use of the 5-HTT or 
TPH2 promoters.  However, these are problematic for a number of reasons.  Developmental 
expression in non-serotonergic neurons/precursors (Bruning and Liangos, 1997; Hansson et al., 
1998; Lebrand et al., 1998; Ortiz-Alvarado et al., 2006) would yield undesired expression using a 
recombinase system.  A non-recombinase mediated system might avoid some of these issues, but 
would lead to the label being expressed in a promoter-dependent fashion; this becomes 
problematic given existing evidence that antidepressant exposure alters expression of 5-HTT and 
TPH2 (Benmansour et al., 1999; Benmansour et al., 2002; Maciag et al., 2006c).   
  
2.2 – Animal Treatment, Housing and Genotyping 
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 Briefly, offspring of ePet-Cre and ROSAR26R-EYFP mice were injected daily from 
postnatal day 2 – 11 with either saline or fluoxetine (10mg/kg, i.p., concentration 2mg/ml) using 
a 30 gauge needle.  This regimen has previously been shown to produce brain levels of 
fluoxetine and norfluoxetine that are approximately equal to those found in adult treatment 
paradigms (unpublished data).  At weaning (P21-P28) mice were tagged and tail-clipped, and 
group-housed under standard conditions until sacrifice.  Animals were not re-caged after 
weaning in order to avoid any potential effects of a novel social environment.  For adult 
treatment experiments, mice were treated with saline or fluoxetine (10mg/kg, i.p., daily) for a 
minimum of 21 days, beginning at 10-12 weeks of age.  
 Tail clips were placed in 60-120 µl lysis buffer containing Proteinase K, and incubated 
for 2 hours at 55 °C followed by heat inactivation (15 minutes at 95 °C).  Primer sequences and 
PCR conditions are included in appendix C.  For ePet-Cre genotyping, paired Cre primers were 
used to detect a band of ~400bp.  For ROSA-EYFP genotyping, a three-primer approach was 
used, yielding bands at ~350bp (knock-in allele) and ~650bp (wild-type allele).  Because the 
ePet-Cre genotyping reaction does not distinguish between transgene heterozygotes and 
homozygotes, no crosses were performed that could result in homozygotes. 
 
2.3 – Immunohistochemistry 
 For experiments investigating the effect of postnatal fluoxetine on serotonergic cell 
density and projections, mice were sacrificed in adulthood (at least four months of age) by 
perfusion.  Briefly, animals were deeply anesthetized with ketamine/xylazine and perfused 
through the left ventricle with ice-cold phosphate buffered saline (PBS), followed by 4% 
paraformaldehyde in PBS.  Brains were dissected and placed in a 4% PFA solution overnight.  
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Following this post-fixation, the brains were cryoprotected through graded sucrose solutions up 
to 30%.  Sectioning was performed on a Leica cryostat at a width of 35µm.  Free floating 
sections were then stored in PBS with 0.05% sodium azide. 
 All immunohistochemistry (IHC) incubations and washes used a rocker.  After brief 
washes in PBS, sections were blocked with 5% normal goat serum (NGS) in PBS with 0.3% 
Triton X-100 (PBST) for two hours at room temperature.  After blocking, anti-EYFP primary 
antibody (rabbit IgG, 4mg/L, Invitrogen A-11122) was applied in PBST with 5% NGS.  Primary 
incubation was performed overnight at 4°C.  Following five washes in PBS (10 minutes each), 
biotinylated goat anti-rabbit secondary was applied (1:300, Jackson Immunolabs).  After a 2 hour 
incubation in secondary and four washes, ABC (avidin-biotin conjugate; Vector Labs) 
amplification was performed as per instructions.  Chromogenic detection was accomplished 
using Sigmafast DAB tablets (3,3’-diaminobenzidine), and sections were mounted on glass 
slides. 
 For optimal visualization of labeled fibers, silver intensification was performed.  Briefly, 
slides were dehydrated through graded ethanols and cleared overnight in citrisolv.  After 
rehydration, slides were placed in prewarmed 1.42% silver nitrate for one hour in a shaking 
water bath set to 56°C.  After a 15-minute wash in running deionized water, slides were 
incubated for 10 minutes in the dark at room temperature in filtered 0.2% chloroauric acid 
(HAuCl3).  Slides were again rinsed for 15 minutes in running deionized water, and then 
transferred to a 5% solution of sodium thiosulfate for five minutes.  After a final rinse and 
dehydration, slides were coverslipped with DPX (distyrene-xylene; Sigma). 
 
2.4 – Stereology 
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 EYFP stained sections spaced at 210 microns were used to obtain quantitative measures 
of fiber density.  Using StereoInvestigator software (MBF Bioscience), outlines of anatomical 
regions were traced using a reference atlas.  The Optical Fractionator tool was used to sample 
25x25 micron frames on a grid of 50x50 microns.  Each fiber passing through the frame was 
counted, as were branch points.  For each defined region, a minimum of three sections was used.  
The optical fractionator was then used to estimate the overall density of innervation; these 
measures were intended not to depict the actual quantity of fibers (i.e., length/volume), but rather 
provide a relative but quantitative estimate of the density of serotonergic fibers in the region. 
  
 
2.5 – Manual Cell Sorting and Transcriptional Profiling 
 
 The methods used for transcriptional profiling were based on those developed in the 
laboratory of Sacha Nelson (Hempel et al., 2007).  After a minimum of 21 days treatment, mice 
were anesthetized with ketamine:xylazine, sacrificed by decapitation, and the brain quickly 
removed to ice-cold ACSF.  The brain was then sliced on a vibratome in the coronal plane using 
a thickness of 400 microns.  
 After slicing, brain sections were allowed to recover for 15 minutes in room-temperature 
ACSF (95:5% O2:CO2 bubbled) prior to 75-90 minutes incubation in pronase (1mg/ml) ACSF 
with DNQX, TTX, and AP5.  Pronase digestion was halted by incubation in ACSF with 1% fetal 
bovine serum.  A slice was chosen representing the dorsal raphé approximately 4.7-5.0mm 
posterior from bregma, at the level of the decussation of the superior cerebellar peduncles.  
Raphe location was confirmed under fluorescence, and a region roughly 1-2 mm3 was manually 
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dissected, comprising the medial dorsal raphé extending from the cerebral aqueduct to the medial 
longitudinal fasciculus (figure xxx).  This tissue was then dissociated by successive trituration 
with glass pipettes flamed-polished to ~600, 300, and 150µm diameter (internal).  Cells were 
then plated on Petri dishes with coverslip bottoms.  After allowing the cells to settle, manual 
sorting began under an inverted fluorescence microscope.  A micropipette, made by melting and 
stretching a plastic 1ml pipette tip and attaching a length of tubing and a mouthpiece, was used to 
pick up fluorescently labeled cells and transfer them to another sorting dish.  Following three 
rounds of sorting, leading to an estimated ~99% purity, 80-150 cells were transferred into RNA 
extraction buffer (PicoPure RNA Kit, MDS Analytical Technologies, USA), and incubated at 
42°C for 30 minutes.  Samples were then spun at 3,000g for 2 minutes, and the supernatant 
frozen at -80°C.  The remainder of the isolation procedure was performed in batches, following 
the kit instructions (including DNase treatment), and RNA was eluted in a final volume of ~11µl. 
! $*!
Figure 2.2 – Region targeted for dissection and dissociation, comprising dorsomedial and 
ventromedial dorsal raphé.  Shown on anti-GFP immunostained section from ePet-
Cre/ROSAR26R-EYFP mouse. 
 Following purification, RNA quantity and quality was assessed using the Agilent 
Bioanalyzer and Pico 6000 RNA chip.  Samples used for microarray hybridization had a mean 
RIN (RNA Integrity Number, a unitless measure 1-10 of degradation) of 7.3 ± 1.0, and 
concentration 122 ± 44 pg/µl, corresponding to a total yield of approximately 1300 ± 400 pg.  
The amplification procedures employed are specified to accurately reproduce mRNA from 
starting quantities as low as 500pg, and with RINs as low as 3.   Samples selected for further 
processing were amplified, fragmented and biotin labeled (using the WTA Pico, Exon, and 
Biotin kits, respectively; NuGEN, USA).  Briefly, cDNA is generated by reverse transcription 
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using poly-A and random chimeric DNA/RNA primers, followed by second strand synthesis 
using primers targeted to unique sequences in the first primer mix.  An isothermal reaction with a 
proprietary DNA polymerase and RNase H then amplifies the cDNA up to 15,000 fold.  The 
Exon module is used to generate sense-transcript DNA suitable for array hybridization from the 
amplified cDNA, and the Biotin module then fragments and labels the ST-DNA.  Hybridization 
and scanning to Mouse Exon 1.0 ST arrays (Affymetrix, USA) was then performed at the 
Genomics Core Facility of Columbia University.   
  
2.6 – Analysis of Microarray Data 
 
Normalization and modeling were performed using Affymetrix Expression Console 
software, using core gene-level probesets and the Robust Multichip Averaging Sketch (rma-
sketch) algorithm.  Visualization of intercorrelation and outlier detection by principal component 
analysis was performed using Expression Console and the R Bioconductor suite.  Probesets 
without an associated gene (or predicted gene) in the Entrez or Ensembl databases were excluded 
from analysis. 
In order to obtain a reference for elucidating unique features of Pet-1 expressing 
serotonergic cells, sample data was downloaded from the Affymetrix web site, consisting of 
three technical replicates of brain homogenate applied to the Mouse Exon 1.0 ST array.  In 
comparing Pet1 DRN samples with brain homogenate, transcripts with expression values below 
the 67th percentile of negative control probesets in at least one third of the samples of both 
conditions were excluded. 
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The MicroArray Quality Control (MAQR) consortium recently reported on a multicenter, 
multiplatform study of best practices, finding that large fold-change in expression values was a 
more reproducible measure of differential expression than stringent statistical testing based upon 
multiple testing correction (Consortium et al., 2006; Shi et al., 2010).  In accord with the 
recommendations of the study authors, differential expression criteria were based on a low 
stringency p-value cutoff (0.05, uncorrected) and relatively more stringent fold-change cutoffs.  
 In order to identify groups of functionally-related genes within sets of differentially-
expressed genes, gene ontology analysis was performed using the Database for Annotation, 
Visualization, and Integrated Discover (DAVID) from the NIAID Laboratory of 
Immunopathogenesis and Bioinformatics (Huang et al., 2009a, b).  In this application, gene lists 
are uploaded and functional annotation applied (including gene ontology, protein/domain 
families, Kyoto Encyclopedia of Genes and Genomes data, etc).  Enrichment for these annotation 
terms is then determined, using a modified Fisher’s Exact test.  Annotation terms are further 
clustered based on shared membership of the submitted genes. 
 Brief descriptions of transcripts identified as differentially-expressed are included in 
several sections.  Where not specifically cited, information was gathered from one or more of the 
following publicly available databases:  
• GeneCards (http://www.genecards.org/) 
• YourFavoriteGene (http://www.sigmaaldrich.com/life-science/your-favorite-
gene-search.html) 
• Ensembl (http://useast.ensembl.org/Mus_musculus/Info/Index) 
• NCBI (http://www.ncbi.nlm.nih.gov/gene) 
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2.7 – Positron Emission Tomography of 5-HT1A Binding 
 
Subjects 
 Twenty-three subjects were recruited by advertisement and referral, and completed the 
study.  Criteria for inclusion were: a diagnosis of MDD based on the Structured Clinical 
Interview for DSM-IV (SCID), no current psychiatric medication or failure of current treatment 
regimen, and age above 18.  Exclusion criteria included current or past diagnosis of 
schizophrenia, schizoaffective disorder, anorexia nervosa, bulimia nervosa, or drug or alcohol 
dependance; substance abuse within the past 2 months; any lifetime history of IV drug use, or 
ecstasy use more than twice; first-degree relative with schizophrenia (for subjects under 33); 
significant medical comorbidity; incapacity to provide informed consent; suicidal ideation; ECT 
within the past 6 months; current, past, or anticipated radiation exposure (e.g., occupational 
exposure, multiple diagnostic X-rays in previous year, prior nuclear medicine studies); 
pacemaker or metallic implant/foreign object; injury resulting in prolonged loss of 
consciousness; current lactation or recent abortion, miscarriage or pregnancy (<2 months); and 
current or planned pregnancy.   
All subjects were free of psychotropic medication for a minimum of two weeks (six 
weeks for fluoxetine) prior to the first PET scan.  Following completion of the baseline Hamilton 
Depression Rating Scale (HDRS) and [11C]WAY-100635 scan, subjects were placed on 
paroxetine (n = 16, 20 - 60 mg daily), citalopram (n = 7, 20 – 40 mg daily), or escitalopram (n = 
1, 10 mg daily), under the care of an NYSPI psychiatrist.  With the exception of small doses of 
short-acting benzodiazepines, no other medication was permitted during the course of the study.  
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Subjects completed a second [11C]WAY-100635 PET scan and HDRS following a mean of 45 
days (range, 29 – 63), and were given the option to continue outpatient for six months. 
All subjects provided written, informed consent following a complete description of the 
study protocol and associated risks.  The protocol was approved by the Institutional Review 
Board of the New York State Psychiatric Institute. 
 
Radiochemistry and Input Function Measurement 
 [C11]WAY-100635 (N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinal) 
cyclohexane carboxamide) was prepared as previously described (Parsey et al., 2000).  Specific 
activity, injected mass, and injected dose did not differ between the pre-treatment and post-
treatment scans (see Chapter 5).  Arterial blood samples were collected from a radial artery 
catheter as previously described (Parsey et al., 2000).  Plasma free fraction (fp) was determined 
in triplicate as previously described (Parsey et al., 2006d), with an adapted procedure for 
normalization of data.  Briefly, fp measurements were trend-corrected according to an estimated 
time trend using smoothing splines on pooled sample data, then fit using a model with two 
random effects (subject and observation nested within subject), and final estimated fP was taken 
as the model prediction for each scan.   
 
Image Acquisition and Analysis 
 Structural T1-weighted MRI images were acquired using either a 1.5T Signa Advantage 
or a 3T Signa HDx system (General Electric Medical Systems, Milwaukee, WI), at a resolution 
of 1.5 x 0.9 x 0.9mm or 1.0mm isotropic, respectively.  PET data were acquired using an ECAT 
EXACT HR+ scanner (Siemens/CTI, Knoxville, TN) as previously described (Parsey et al., 
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2000).  Briefly, a ten minute transmission scan was acquired, followed by the bolus injection 
over 45 seconds of [C11]WAY-100635 and a 110 minute emission scan consisting of twenty 
frames of increasing duration (3 x 20s, 3 x 1min, 3 x 2min, 2 x 5 min, 9 x 10 min).   
 Image analysis was conducted using custom routines created for MATLAB 2006b (The 
Mathworks, Natick, MA) and functions from the FMRIB Software Library (FSL; FMRIB, 
Oxford, UK) and Statistical Parametric Mapping (SPM5; University College London, UK).  
Parameters for motion correction of PET scans were determined by applying FMRIB’s Linear 
Image Registration Tool (FLIRT) to denoised data.  Briefly, each frame was successively 
registered to the mean of already-registered frames, beginning with the eighth frame.  Movies of 
sagittal, axial, and coronal slices were then manually inspected for residual motion.  
Coregistration to MRI, also using FLIRT, involved performing multiple registrations using 
various cost functions and target images (e.g., T1, probabilistic gray matter map from SPM, etc).  
Overlays for each coregistration were then manually inspected by a trained technician, and the 
best fit selected.  Finally, the concatenated motion correction and coregistration transforms were 
applied to each frame of the scan, moving the PET data into MRI space. 
 Twelve of thirteen regions of interest (ROIs) were hand drawn on each subject’s MRI by 
a trained technician and relying on standard human brain atlases (Duvernoy; Talairach & 
Tournoux).  The ROIs used were orbital prefrontal cortex (OPFC), medial PFC (MPFC), 
dorsolateral PFC (DLPFC), anterior cingulate (ACC), cingulate cortex (CIN), amygdala (AMY), 
hippocampus (HIP), parahippocampal gyrus (PIP), insular cortex (INS), temporal cortex (TEM), 
parietal cortex (PAR), and occipital cortex (OCC).  Cortical ROIs were further masked using the 
probabilistic gray matter map produced by SPM’s MRI segmentation procedure.  Data for each 
ROI represent the average of the left and right sides. 
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Because the boundaries of the median and dorsal raphe nuclei (RN) are not identifiable 
on MRI, the RN ROI was drawn directly on the PET image. Briefly, an ellipsoid measuring 
12mm AP x 12mm ML x 26mm RC was manually placed on the mean PET image for each scan. 
This volume completely encompassed the high [11C]WAY-100635 binding region of the 
posterior midbrain. Also, a cylindrical region of reference was drawn in the cerebellar white 
matter, as this region of cerebellum is virtually devoid of 5-HT1A receptor (Parsey et al., 2005b).  
Finally, time-activity curves for each ROI were constructed from the mean voxel intensity in 
each frame. 
The outcome measure BPF was used for all statistical analyses, as it is the closest readily 
achievable surrogate to Bmax: BPF is equal to Bmax/KD, and KD is not believed to vary among 
human subjects.  Time activity curves were fit using the arterial input function and a two tissue 
compartment model, in which the ratio K1/k2 is assumed to be constant throughout the brain, 
including the reference region, cerebellar white matter.  ,-.!/01!/2345627!89!0!160:70;7!2;;<;=!><?@A627!A13:4!0!8<<616;0@!0B4<;365?!6<!2163?062!2;;<;!3:!?2608<B362=!@B01?0=!0:7!8;03:!7060!CD472:!0:7!E0;@29=!#++'FG!!Statistical analysis was performed in R (R Project for 




Genotyping for the serotonin 1A receptor C-1019G promoter polymorphism was 
conducted by PCR using allele-specific primers (Wu and Comings, 1999), using conditions as 







Chapter 3:  
The Transcriptome of Dorsal Raphé Serotonergic Neurons 
 
  
 The innovation of technologies such as expression microarrays and RNA-seq has given 
researchers the ability to measure gene expression in a global and unbiased way.  This has led to 
the use of the term transcriptome to describe the snapshot of genes expressed, at a given time or 
under particular experimental conditions.  However, the heterogeneity of cell types, particularly 
in the brain, presents a problem.  In a theoretical sense, transcriptome should refer to the state of 
a single cell, but in practice this is technically quite difficult.  While early studies frequently used 
homogenates of organs, brain regions, etc., there is growing recognition that the ability to at least 
restrict to a defined cell type is critical (Nelson et al., 2006).  At the descriptional level, such data 
afford the opportunity to precisely define transcriptional differences between cell types as well as 
identify uniquely expressed genes that might serve as drug targets or genetic markers.  In 
experimental studies, these data can elucidate which specific cell types are involved in the 
manipulation, and how they are effected. 
 In this chapter, data are presented on the transcriptional characteristics of serotonergic 
neurons of the dorsal raphé.  Our study represents the first characterization of the transcriptome 
of DRN 5-HT neurons in the mouse; future work may complement the findings presented herein 
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by investigating the transcriptome in subtypes of serotonergic neurons, defined by raphé subfield, 
projections, genetic markers, etc.   
 As a note of explanation, expression values provided through Affymetrix’s rma-sketch 
algorithm for summarization and normalization of microarray results are on a log2 based scale.  
In comparing a given gene between two conditions, a difference of 1 thus corresponds to a 
relative doubling of expression, a difference of 2 to a quadrupling, etc.  In some results and 
figures, expression is also reported as a percentage or fold-change for improved readability.  In 
many cases, ‘volcano’ plots are used; these are scatterplots of the difference in log2 values 
plotted against the –log-10(p-value), thereby showing both the magnitude and statistical 
significance of gene expression changes. 
  
3.1 – Positive controls and Serotonergic Genes 
 In order to determine the utility of comparing the transcriptome of Pet1-labeled DRN 
neurons with that of the whole brain, we first sought to analyze differential expression of genes 
that are known to be specifically or highly expressed in serotonergic neurons.  These include the 
key serotonin biosynthetic genes Tph2 and dopa decarboxylase (Ddc), SERT (Slc6a4), Vmat2 
(Slc18a2), MAOB, and Pet1 (Fev).  Using stringent criteria of p < 0.001 and > 800% expression 
relative to whole brain, we find all of these genes significantly overrepresented (figure 3.1; table 
3.1).   
 Expanding our purview to include other genes related to serotonergic neurons, a number 
of interesting points arise (figure 3.2).  Among the 5-HT receptors, only the 1A, 1D, and 5B  
receptors appear enriched in serotonergic neurons.  Vmat2 is the clearly most-enriched of the 
vesicular monoamine transporters, and notably, MAOA appears to be detectable within the raphé 
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serotonergic neurons.  Among the genes specifying serotonergic cell fate, Pet1 (Fev), Gata2, 
Gata3, and Lmx1b appear to remain expressed in adulthood (figure 3.3).  In situ hybridization for 
MAOA, Pet1, Gata2-3, and Lmx1b from the Allen Brain Atlas provide complementary evidence 
for expression of these genes in the dorsal raphé (supplemental data, section B.2). 
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Figure 3.1 – A priori genes expected to be overrepresented in Pet1-labeled DRN neurons 
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Figure 3.2 – Genes related to serotonergic neurotransmission
 
 




3.2 – Exploration of the expression of selected gene classes 
 Because the gene expression pattern of serotonergic neurons is largely unknown, we then 
sought to identify enriched members of several gene classes.  Specifically, we sought to identify 
relative expression of transcripts that are likely to specify the developmental and functional 
characteristics of serotonergic neurons:  neurotransmitter receptors, ion channels, regulators of G 
protein-coupled receptor signaling, growth factors, and regulators of axon guidance. 
 Glutamate transmission-related genes display noticeably low relative expression (figure 
3.4), but this presumably is largely a result of their abundant expression throughout the brain.  
Nonetheless, the vesicular glutamate transporter Vglut3 (Slc17a8) is strikingly highly expressed 
in serotonergic neurons (1084% of whole brain extract, p = 0.00043). Also, Gria4, AMPA 
subunit !4, is moderately (49%) but significantly (p = 0.001) enriched.  Both findings are 
corroborated by in situ hybridization data indicating relatively high dorsal raphé expression 
(figure 3.5): Vglut3 in both dorsal and median raphé, while Gria4 is more focused in median 
DRN. 
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 We also investigated expression of receptors for the main inhibitory neurotransmitters of 
the CNS, GABA and glycine (figure 3.6).  Relative expression of most GABA receptors is low, 
again presumably because of the high expression levels present in brain homogenate.  Among 
the transcripts found in increased abundance in serotonergic neurons are the glycine receptor 
subunits !1 and !2 (Glra1 and Glra2; figure 3.7), the GABA-A receptor "3 subunit (Gabrb3), 
and GABA-A receptor-associated protein-like 2 (Gabarapl2).  Because colocalization of 5-HT 
and GAD67 immunoreactivity has previously been reported (Fu et al., 2010), we were also 
interested in the possibility of co-release; however, we found no evidence for enrichment of 
GABA vesicular transporter (Slc32a1) or the 65/67kDa glutamate decarboxylase enzymes (Gad1 
and Gad2).   
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Figure 3.6 – Expression of GABA/Glycine receptors  





The raphé nuclei receive innervation from major neuromodulatory nuclei such as the 
locus coeruleus and ventral tegmental area.  Therefore, we also sought to characterize expression 
of receptors for norepinephrine, dopamine, and acetylcholine, as well as several genes related to 
these signaling pathways (figure 3.8).  No receptors showed an enrichment of expression in the 
serotonergic samples, although several were expressed at levels comparable to whole-brain, 
including the "3 adrenergic receptor (Claustre et al., 2008), several nicotinic acetylcholine 
receptors, and !1b and !2b adrenergic receptors.  The only gene showing relatively greater 
expression was acetylcholinesterase (Ache; 211% of whole brain, p = 4.57 x 10-5), a finding 
supported by Allen Brain Atlas in situ hybridization data (figure 3.9).   
 
Figure 3.8 – Neuromodulator receptors and related genes 
 
 





 The raphé nuclei show expression of many neuropeptides, but the degree of expression 
within 5-HTergic neurons is variable or unknown (Fu et al., 2010); expression of neuropeptide 
receptors could also indicate which of these transmitter systems might function in local circuits 
of the raphé.  There already exists ample evidence of a role for the endocrine system in mood 
disorders, in particular the role of estrogen, thyroid hormones, and the hypothalamic-pituitary-
adrenal axis.  Likewise, the importance of immune-brain signaling is increasingly recognized as 
a potential influence in mood disorders (Capuron and Miller, 2011), so the action of immune 
cytokines on serotonergic function is potentially important.  We therefore sought to broadly 
characterize expression of these genes in serotonergic neurons of the dorsal raphé. 
 Among the neuropeptides/receptors, a small number of genes were significantly enriched 
in the 5-HTergic DRN samples (figure 3.10).  Notably, urocortin-2 (Ucn2), a ligand for the CRF 
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type 2 receptor, is of increased abundance to a very high degree of significance (p = 1.12 x 10-6).  
The calcitonin gene-related peptide-receptor component protein (Crcp), a modulatory component 
of the cAMP-stimulating CGRP receptor, is also enriched (p = 0.0050), corroborated by earlier 
immunohistochemical work (Ma et al., 2003).  Expression of CGRP has been reported in non-
serotonergic neurons of the raphé, raising the possibility that this peptide has a role in local 
modulation of serotonergic activity (Fu et al., 2010).   
 In investigating the expression of hormone receptors and related genes, there are several 
interesting findings to note (figure 3.11).  Most obviously, prostaglandin E2 synthase 3 (Ptges3) 
is enriched ~21 fold (p = 2.5 x 10-8, figure 3.12, left); this gene appears to function both as a 
component of the progesterone receptor complex, and in the synthesis of PGE2, which has 
previously been shown to homeostatically regulate synaptic strength in cortical slice culture 
(Koch et al., 2010).  The estrogen receptor-binding fragment-associated gene-9 (Ebag9), also 
known as receptor-binding cancer antigen on SiSo cells (RCAS1), which appears to have a role 
in release of large dense-core vesicles (Rüder et al., 2005) was found to be enriched in DRN 
serotonergic neurons (p = 4.78 x 10-4).  Additionally, a moderate overrepresentation of estrogen 
receptor " (Esr2) is observed (p = 0.0049), supported by in situ data from the Allen Brain Atlas 
(figure 3.12, right) which suggests perhaps a median subset of raphé 5-HT cells may express 
ER".  Among immune mediators, interleukin 1 receptor type I (Il1r1) is clearly of very high 
expression (figure 3.13).   
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Figure 3.10 – Neuropeptides and receptors 
 
Figure 3.11 – Hormone receptors and related genes
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Figure 3.12 – Prostaglandin E2 synthase 3 and estrogen receptor 2 (") (Allen Brain Atlas)
 
 










 The electrophysiological characteristics of neurons are heavily dependent on the 
complement of ion channels expressed in the channel membrane.  We therefore investigated the 
transcriptome data to identify channels overrepresented in serotonergic neurons.  As with 
glutamate and GABA receptors, expression of many of these genes is likely high throughout the 
brain, so it would only be expected that channels with some specificity to the dorsal raphé would 
show significantly elevated relative expression.  Such channels might yield promising drug 
targets. 
 We investigated calcium, potassium, sodium (figure 3.15) and chloride channels (not 
shown).  Among all of these categories, the type IX voltage gated sodium channel alpha subunit 
(Scn9a; Nav1.7) was the most highly enriched in the Pet1 DRN samples (49-fold, p = 2.9 x 10-8).  
This gene is notable for its peripheral involvement in nociception; in the CNS, however 
expression appears to be limited to the DRN, arcuate nucleus of the hypothalamus, and the dorsal 
motor nucleus of the vagus (figure 3.16, right panel).  Interestingly, duloxetine has recently been 
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found to be a potent (1.79µM) blocker of the closed conformation (Wang et al., 2010).  Another 
channel identified as enriched in 5-HTergic neurons is the subfamily J, member 14, inwardly-
rectifying potassium channel (Kcnj14; 4.28-fold enrichment; p = 5 x 10-4).  Inspection of the in 
situ data (figure 3.16, left panel) shows very small clusters of intensely labeled neurons, near the 
medial longitudinal fasciculus; this staining pattern could represent a small subset of 5-HT 




Figure 3.15 – Ion Channel Expression
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Figure 3.16 – ISH of selected ion channels (Allen Brain Atlas)
 
 
Additional gene classes of interest included: the RGS family (regulator of G protein 
signaling), due to their potential involvement in desensitization of 5-HT autoreceptors; growth 
factors/neurotrophins and receptors, because of evidence implicating them in depression and 
antidepressant function; and synapse-associated proteins, with the goal of identifying potentially 
novel markers of 5-HT terminals.  Volcano plots for these analyses are included in appendix B, 
figure B.3-5.   
 Genes which emerge as highly enriched in the Pet1-labeled DRN samples include: Rgs2 
(7.6-fold, p = 3.16 x 10-8), NGF receptor-associated protein-1 (3.5-fold, p = 5.79 x 10-7), 
syntaxin-4A (11.2-fold, p = 2.35 x 10-8), !-synuclein (3.9-fold, p = 7.07 x 10-8), and voltage-
dependent anion channel 3 (4.1-fold, p = 1.01 x 10-5).  In situ hybridizations for these genes from 
the Allen Brain Atlas are presented in figure 3.17.  Rgs2 has previously been identified as highly 
expressed in the dorsal raphé (Grafstein-Dunn et al., 2001), and polymorphisms in the human 
gene have been associated with anxiety (Leygraf et al., 2006; Smoller et al., 2008) and suicide 
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risk (Cui et al., 2008).  Male mice with reduced Rgs2 expression show increased anxiety-like 
behavior in the elevated plus maze and the novelty suppressed feeding test, and increased 
immobility in the forced swim test, as well as reduced 5-HT1A receptor sensitivity as measured 
by agonist-induced hypothermia.  NGFrap1, also known as p75 neurotrophin receptor-associated 
cell death executor (NADE), mediates the pro-apoptotic actions of NGF (Mukai et al., 2000).  
Syntaxin-4A (Stx4a) is localized to dendritic spines, where it is believed to play a role in 
receptor insertion and long term potentiation (Kennedy et al., 2010).  Alpha-synuclein is best 
known for its genetic role in Parkinson’s disease and Lewy body dementia. Its precise function is 
not known, but it clusters in presynaptic terminals, and is believed to regulate the trafficking of 
monoamine transporters (Oaks and Sidhu, 2011).  Expression of !-synuclein is elevated in the 
raphé of male mice subjected to repeated social defeat (Kudryavtseva et al., 2010).  Voltage-
dependent anion channel 3 (Vdac3) is a mitochondrial outer membrane channel for nucleotides, 
serving as a critical regulator of ATP/ADP flux and the balance of reactive oxygen species.  
Notably, Vdac3 was recently identified in a proteomic analysis of !-synuclein binding partners 













3.3 – A posteriori genes showing overrepresentation in serotonergic DRN neurons 
 
 We next sought to identify genes most highly expressed in the Pet1-labeled DRN samples 
without any a priori assumptions regarding gene class.  A complete listing of the 41 genes 
showing at least 16-fold enrichment and p < 0.001 is presented in Table 3.2, and plotted in figure 
3.18.  As reported in section 3.1, marker genes for 5-HT neurons present in this list include 
SERT (Slc6a4), TPH2, dopa decarboxylase, and Vmat2 (Slc18a2).  Two genes involved in 
tetrahydrobiopterin biosynthesis (a cofactor for aromatic amino acid hydroxylases such as TPH 
and TH) are also highly enriched: GTP cyclohydrolase 1 (Gch1) and GTP cyclohydrolase I 
feedback regulator (Gchfr).  Two genes identified in the investigation of previous gene classes 
(previous section) also appear in this list: Nav1.7 (Scn9a) and prostaglandin E synthase 3 
(Ptges3).   
 In order to identify gene functions that are overrepresented among these genes, we 
performed gene ontology analysis, using genes showing 8-fold enrichment and p < 0.001 (91 in 
total; table included in appendix B).  Several clusters (of related ontology terms) were identified 
in these data:  
1. Ribosomal / translation: Rpl23, Rpl14, Mrps12, Ubc, Rps27l, Rpl38, Snrnp35, Srp9, 
Mrto4, Pnn (p = 6.86 x 10-5). 
2. Neurotransmitter transport: Slc17a8, Stx4a, Slc6a4, Slc18a2, Slc22a3 (p = 0.00059). 
3. Nitrogenous compound/biogenic amine synthesis: Ddc, Atp5e, Nme3, Pcbd2, Gata3, 
Gch1, Tph2 (p = 0.0031). 
4. Mitochondrial/Parkinson’s Disease: Atp5e, Ndufa2, Pcbd2, Mrps12, 2900010m23rik, 
Maob, Prdx2, Ndufa1, Prdx1, Immp1l, Nme3, Acyp2, Cox17 (p = 0.00389). 
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5. RNA recognition motif/RNA-binding: Dnajc17, Fus, Rbmx2, Snrnp35, Srp9 (p = 
0.0145).   
 The presence of the third group in this list is fairly self-evident: serotonergic neurons by 
definition express synthetic proteins for monoamine synthesis at rates much higher than would 
be expected in whole brain homogenate.  Likewise, neurotransmitter transporters are a key 
specifier of neuronal cell type, hence the presence of SERT, Vglut3, Vmat2, and the 
extraneuronal monoamine transporter Slc22a3.  On the other hand, the overrepresentation of 
mitochondrial and ribosomal proteins was not anticipated.  A potential explanation would be that 
5-HTergic neurons, in contrast to other neurons and glia, have extensive axon projections 
throughout the CNS; elevated mitochondrial and ribosomal proteins might be necessary to cater 
to the higher energetic demands, and protein synthesis required to accommodate this increased 
cytoplasmic volume.  The final category, RNA binding, poses a more difficult question.  
Dnajc17 and Rbmx2 have unknown functions, but possess the RNA recognition motif.  Fus 
(fused in sarcoma) is a component of the heterogeneous nuclear ribonucleoprotein complex, 
which is involved in DNA repair, regulation of transcription, RNA splicing, and mRNA export; 
mutations have been associated with familial amyotrophic sclerosis.  Snrnp35 (small nuclear 
ribonucleoprotein 35kDa) is a component of the U12-type spliceosome.  Srp9 (signal recognition 
particle 9kDa) has a somewhat different function, binding to translating ribosomes in which the 





Table 3.2 – Transcripts highly overrepresented in DRN samples 
Symbol Name Log2 (DRN/Brain) Fold-change p value 
Mrto4 MRT4, mRNA turnover 4, homolog (S. cerevisiae) 7.08 135.3 1.9E-07 
Ubc ubiquitin C 7.01 128.6 1.7E-06 
Gchfr GTP cyclohydrolase I feedback regulator 6.38 83.4 3.0E-11 
Gch1 GTP cyclohydrolase 1 5.92 60.3 3.0E-08 
Tph2 tryptophan hydroxylase 2 5.89 59.3 1.7E-12 
Tmsb15l thymosin beta 15b like 5.88 58.7 1.3E-05 
Scn9a sodium channel, voltage-gated, type IX, alpha 5.63 49.4 2.9E-08 
Cryba2 crystallin, beta A2 5.50 45.2 1.7E-07 
Slc6a4 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 5.47 44.4 8.5E-13 
Rpl38 ribosomal protein L38 5.44 43.5 2.0E-08 
Ndufa2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2 5.17 36.0 1.3E-08 
Rnf7 ring finger protein 7 5.06 33.3 3.3E-09 
Asb4 ankyrin repeat and SOCS box-containing 4 5.06 33.3 1.1E-08 
Selk selenoprotein K 4.96 31.0 3.9E-05 
Gstm6 glutathione S-transferase, mu 6 4.91 30.1 2.5E-07 
Gltscr2 glioma tumor suppressor candidate region gene 2 4.83 28.4 6.3E-07 
Tceb2 transcription elongation factor B (SIII), polypeptide 2 4.72 26.3 3.7E-05 
Dgkk diacylglycerol kinase kappa 4.64 24.8 3.4E-08 
Slc18a2 solute carrier family 18 (vesicular monoamine), member 2 4.63 24.8 1.2E-10 
Glo1 glyoxalase 1 4.63 24.8 3.0E-08 
Tceal5 transcription elongation factor A (SII)-like 5 4.57 23.8 4.4E-09 
Esd esterase D/formylglutathione hydrolase 4.57 23.8 4.4E-04 
Rhbdd2 rhomboid domain containing 2 4.53 23.1 1.2E-06 
Srp9 signal recognition particle 9 4.48 22.3 4.0E-08 
Ccdc55 coiled-coil domain containing 55 4.48 22.2 4.8E-08 
Prdx2 peroxiredoxin 2 4.47 22.1 2.3E-04 
Ddc dopa decarboxylase 4.41 21.3 3.3E-10 
Ptges3 prostaglandin E synthase 3 (cytosolic) 4.41 21.3 2.5E-08 
Pnn pinin 4.39 21.0 7.6E-08 
Hmgn5 high-mobility group nucleosome binding domain 5 4.36 20.5 6.4E-05 
Gtf3c6 general transcription factor IIIC, polypeptide 6, alpha 4.35 20.4 1.1E-07 
A830039N20
Rik RIKEN cDNA A830039N20 gene 4.35 20.4 2.1E-05 
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Table 3.2 (continued) 
Symbol Name Log2 (DRN/Brain) Fold-change p value 
Rpl14 ribosomal protein L14 4.35 20.3 5.3E-06 
Supt4h1 suppressor of Ty 4 homolog 1 (S. cerevisiae) 4.32 19.9 8.2E-06 
Ik IK cytokine 4.31 19.8 8.5E-09 
2410022L05Rik RIKEN cDNA 2410022L05 gene 4.26 19.2 1.2E-09 
Slc10a4 solute carrier family 10 (sodium/bile acid cotransporter family), member 4 4.18 18.1 1.1E-09 
Esm1 endothelial cell-specific molecule 1 4.05 16.5 3.4E-06 
Immp1l IMP1 inner mitochondrial membrane peptidase-like (S. cerevisiae) 4.04 16.5 7.9E-05 
Tmem114 transmembrane protein 114 4.03 16.3 2.2E-05 
Amigo2 adhesion molecule with Ig like domain 2 4.01 16.1 9.5E-07 
 
Figure 3.18 – Transcripts highly overrepresented in DRN samples 
 






















































Presented here are brief summaries of the function of genes (not previously described) in table 
3.2: 
• Mrto4 – a gene of unknown function, highly homologous to P0 ribosomal protein, but 
localized to the nucleus.  
• Ubc – a polyubiquitin precursor. 
• Gch1 – catalyzes GTP > 7,8-dihydroneopterin-3P conversion, the first and rate limiting 
step of tetrahydrobiopterin synthesis. 
• Gchfr – Mediates feedback inhibition of Gch1 by tetrahydrobiopterin (Figure 3.19) 
• Tmsb15l – Cytoskeleton organization; sequestration of actin monomer. 
• Cryba2 - "-crystallins are components of the lens of the eye (Figure 3.19). 
• Rpl38 – A component of the 60S ribosome subunit. 
• Ndufa2 – Component of mitochondrial complex I (NADH:ubiquinone oxidoreductase); 
mutations are associated with early-onset neurodegeneration (Leigh syndrome). 
• Rnf7 – Component of E3 ubiquitin ligase complex; anti-apoptotic, possibly via regulation 
of redox balance. 
• Asb4 – Component of E3 ubiquitin ligase complex; expressed in pro-opiomelanocortin 
and NPY neurons in energy homeostasis regions of hypothalamus (Li et al., 2010); in situ 
hybridization suggests expression in a particular subset of DRN neurons (figure 3.19). 
• Selk – selenium-containing protein localized to ER; functions as an antioxidant. 
• Gstm6 – transferase for reduced glutathione (redox balance; xenobiotics). 
• Gltscr2 – tumor suppressor; possibly functions in PI3P pathway. 
• Tceb2 – a.k.a. elongin B; involved in both transcriptional elongation and E3 ubiquitin 
proteolysis. 
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• Dgkk – metabolizes DAG to phosphatidic acid, thus terminating PKC signaling; 
selectively inhibited in the face of oxidative stress. 
• Glo1 – regulator of redox balance; anti-apoptotic; regulated by Rgs2; manipulation of 
Glo1 in cingulate cortex is associated with altered anxiety-like behavior (Hovatta et al., 
2005). 
• Tceal5 – transcription elongation factor-like; function unknown. 
• Esd – serine hydrolase; possibly involved in recycling of sialic acids and gangliosides. 
• Rhbdd2 – transmembrane gene of unknown function; over-expressed in breast cancer. 
• Ccdc55 – regulator of mRNA splicing; nuclear speckle localization. 
• Prdx2 – antioxidant enzyme; antiapoptotic. 
• Pnn – regulator of both transcription and mRNA splicing; nuclear speckle localization.   
• Hmgn5 – transcription factor; prevents chromatin compaction. 
• Gtf3c6 – part of general transcription factor TFIIIC, involved in transcription of tRNA, 
rRNA, etc. 
• Rpl14 – component of 60S ribosomal subunit. 
• Supt4h1 – complex component regulating transcriptional elongation. 
• Ik – unknown; nuclear localization, inhibitor of interferon signaling. 
• 2410022L05Rik – Copr5; regulator of histone methylation (Lacroix et al., 2008) 
• Slc10a4 – orphan transporter; localizes to synapses of cholinergic and monoaminergic 
(Vmat2+) neurons (Burger et al., 2011). 
• Esm1 – induced by TNF and interleukin 1"; expression elevated in a variety of cancers; 
possibly involved in angiogenesis and tumor invasion. 
! (#!
• Immp1l – part of the inner mitochondrial membrane peptidase complex; removes 
targeting peptide from nuclear-encoded proteins transported to mitochondria. 
• Tmem114 – possible voltage dependent calcium channel; translocation causes congenital 
cataracts (Maher et al., 2011). 
• Amigo2 – transmembrane protein with possible neuronal cell adhesion function; 
promotes neurite extension and neuron survival (Kuja-Panula et al., 2003; Ono et al., 
2003) .  
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Figure 3.19 – ISH of Selected Genes (Allen Brain Atlas)  
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3.4 – Conclusions 
 In this chapter, I have reported findings concerning the gene expression profile of Pet1-
labeled neurons of the dorsal raphé.  The comparison of Pet1-labeled DRN neurons with whole 
brain homogenate does have limitations.  The inclusion of astrocytes and oligodendrocytes could 
have the effect of diluting certain neuronal genes, potentially causing false positives that are 
simply neuron-enriched.  Of course, comparison with another identified class of neuron would 
only provide relative transcriptomes of the two specific cell types under consideration.  Ideally, a 
large number of specified neuron types would be compared in the confines of a single 
experiment; we are planning to integrate our data with those of Ken Sugino and Sacha Nelson, 
who used nearly identical methods to probe the transcriptome of locus coeruleus noradrenergic 
neurons, as well as layer V pyramidal and somatostatin-positive inhibitory cortical neurons.  
Regardless, the availability of in situ hybridization data from the Allen Brain Atlas provides 
excellent corroboration of results: while either data source alone has potential pitfalls (e.g., false 
positives in the array data, non-serotonergic raphé expression in the ISH data), the combination 
of both provides compelling evidence for expression in DRN 5-HTergic neurons.   
There is substantial evidence that serotonergic neurons are themselves a heterogeneous 
population, in terms of electrophysiological characteristics, projection targets, neuropeptide 
expression, developmental ontogeny, etc. (Kocsis et al., 2006; Fu et al., 2010; Calizo et al., 2011; 
Kiyasova et al., 2011).  The transcriptome characterization of these subtypes is beyond the scope 
of the present study, but it is hoped these data can provide a foundation for future work 
comparing 5-HTergic neuronal subtypes defined by raphé subfield, patterns of projection, 
expression of genetic markers, or other methods.  In this context, it is noteworthy that ISH data 
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for many of the transcripts identified in our data are suggestive of expression within specific 
subsets of 5-HT neurons. 
In comparison with whole brain homogenate, a priori ‘positive control’ genes show 
substantial enrichment (e.g., TPH2, MAOB, SERT, VMAT2, dopa decarboxylase), suggesting 
that the experimental methods are effective at identifying serotonergic neuron-specific 
transcription.  Also as expected, 5-HT1 receptors show modest but significant overrepresentation, 
while excitatory 5-HT receptors do not.  Of the embryonic transcriptional network that specifies 
serotonergic neurons, Pet1, GATA3, GATA2, and perhaps Lmx1b appear to retain expression 
into adulthood.  Our data also provides evidence for 5-HTergic neuron expression of several 








Chapter 4:  
 




 As described in the introductory chapter, fluoxetine treatment during a developmental 
critical window leads to an adult phenotype of anxiety-like and novelty-averse behavior, 
replicating many of the effects of SERT knockout.  The biological mechanisms underlying this 
process are unclear, but a number of possibilities can be surmised.  First, because postnatal 
fluoxetine treatment does not alter anxiety-related behavior in SERT knockout mice (Ansorge et 
al., 2004), it is apparent that the phenotype is dependent on blockade of the transporter.  The 
impairment of serotonin clearance during the critical period presumably leads to increased 
activation of 5-HT receptors expressed during this time.  Serotonin receptor signaling, 
particularly via 5-HT1A and 5-HT1B, has a demonstrated role in differentiation, apoptosis, neurite 
outgrowth, and synaptogenesis; these receptors are developmentally expressed in both target 
tissues, and as autoreceptors on 5-HTergic neurons.  Therefore, potential biological effects of 
postnatal SERT blockade can be broadly categorized as being either ‘presynaptic’ or 
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‘postsynaptic’, i.e., effecting either the development of serotonergic neurons via feedback, or of 
other neuronal or glial cell types expressing serotonergic receptors.   
 In this chapter I present data concerning the former: the influence of postnatal SSRI 
treatment on serotonergic neurons themselves.  Prior data indicate a reduction in in vivo baseline 
firing rate (unpublished data), and a reduction of SERT and TPH immunoreactivity in cortex and 
dorsal raphé, respectively (Maciag et al., 2006a).  Alterations in firing rate could be intrinsic to 
the neuron (e.g., enhanced autoreceptor sensitivity) or circuit-mediated.  Likewise, changes in 
SERT expression might reflect a reduction in protein expression and/or trafficking, or a change 
in connectivity.  Therefore, we have sought to characterize the 5-HTergic neurons of postnatal 
fluoxetine treated mice on three levels: anatomical, transcriptional, and electrophysiological. 
 
4.1 – Postnatal SSRI Treatment Alters Serotonergic Innervation of Prefrontal Cortex 
 Given both the evidence of 5-HT feedback inhibition of serotonergic neurons during 
development, and previous work reporting reduced SERT expression in the cortex, we sought to 
determine if postnatal fluoxetine (PNFLX) treatment would disrupt normal serotonergic 
innervation of key brain structures involved in emotional behavior.  The medial prefrontal cortex 
was selected as the initial target of study for two principal reasons: firstly, evidence of altered 
infralimbic pyramidal cell dendritic morphology in PNFLX mice (Tahilia Rebello, personal 
communication), and secondly, the highly bidirectional nature of connection between mPFC and 
raphé (Hajós et al., 1998).   
 We elected to use Pet1-Cre/R26R-EYFP mice for axon tracing, because of the potential 
confounds of altered abundance of SERT or 5-HT, and the improbability of a PNFLX influence 
on expression from the ROSA locus.  As described in Methods, mice treated with fluoxetine or 
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saline from P2-P11 were sacrificed in adulthood (>4 months) and immunostained for GFP, 
revealing intense staining of neuronal cell bodies in the raphé nuclei (example images in 
appendix figure B.6).  No cell body staining was visible outside of the brainstem.  Stains of 
R26R-EYFP heterozygotes showed no immunoreactivity (not shown), indicating that 
spontaneous recombination was not occurring.  Stereological technique was used to quantify the 
density of stained fibers, by measuring the intersection of axons with the counting grid.   
 In PNFLX mice, we found reduced density of Pet1/EYFP-labeled fibers in medial 
prefrontal cortex (figure 4.1).  Infralimbic, prelimbic, and anterior cingulate (IL, PL, AC) 
subregions all showed similar 40-60% decreases, with PL and IL reaching significance; no layer-
specific change was discernable, although detailed layer-by-layer analysis was not performed.  
The thickness of sections and quality of staining did not permit accurate, quantitative 
differentiation of M and D type fibers; however, observation suggests that thicker and thinner 
fibers are equivalently reduced in the PNFLX samples.   
We have also found altered dendritic arborization of hippocampal CA3 pyramidal 
neurons in PNFLX mice (Tahilia Rebello, unpublished data); therefore, we decided to investigate 
serotonergic projections in this region as well.  A similar reduction in fiber density was observed 










Figure 4.2 – Reduced Density of Pet1/EYFP Fibers in Hippocampal CA3 Region 
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4.2 – Electrophysiological Characterization of PNFLX Mice 
 The observation of reduced in vivo firing rate of 5-HTergic neurons at baseline suggests a 
number of possible explanations.  The cells could be intrinsically less excitable, through 
alteration of ion channels or second messenger systems.  Similarly, a shift in balance in the 
expression of excitatory and inhibitory neurotransmitter receptors could account for reduced 
firing rate.  Alternatively, changes in the function or anatomy of excitatory and/or inhibitory 
neurons driving serotonergic activity might be involved.  In order to address these possibilities, 
patch-clamp recording of slices from ePet-Cre/EYFP PNFLX mice were performed by our 
collaborators in the laboratory of Sheryl Beck. 
 Fundamental properties of vmDRN 5-HTergic neurons were not altered in PNFLX mice 
(table 4.1).  Neither resting membrane potential (RMP) or action potential threshold displayed 
any significant alteration between groups.  The input-output relationship of current injection to 
spike frequency was also unchanged.  At the circuit level, the frequency of spontaneous 
inhibitory postsynaptic currents (IPSCs) was found to be substantially greater in PNFLX mice.  
The frequency of excitatory postsynaptic currents was also somewhat increased, but did not 
reach statistical significance.  
 




4.3 – Transcriptional Alterations in PNFLX Mice 
 
 The persistence of the PNFLX phenotype into adulthood may be manifested in the  
‘cellular phenotype’ of 5-HT neurons.  Changes in intrinsic properties could results from altered 
expression of ion channels, receptors, growth factors, etc., maintained by epigenetic and/or 
transcriptional network programming during the developmental critical period.  We therefore 
performed transcriptional profiling of adult PNFLX and saline treated animals in order to 
identify differentially regulated genes that might shed light onto the adult phenotype, and 
complement the anatomical and physiological findings reported above.   
 We had a number of a priori gene classes of interest: serotonin receptors and related 
genes, receptors for other neurotransmitters and peptides, ion channels, regulators of neuronal 
development, growth factors/receptors, components and regulators of GPCR intracellular 
signaling cascades, and epigenetic modulators (histone & DNA methylation).  In comparison to 
the magnitude of differential expression seen in chapter 3, we anticipated much more subtle 
differences here: rather than comparing a homogenous cell type with whole brain, we are 
measuring the effects of a non-toxic drug months after administration.  A p-value cutoff of 0.05 
and a $log2 score of 0.8074 (corresponding to values more than 175% or less than 57% of 
control samples) were used to select genes that might be differentially expressed.  Note that 
treatment conditions are abbreviated as followed: pS and pF for postnatal saline and fluoxetine, 
aS and aF for adult treatments. 
 Figure 4.3 shows a basic volcano plot (cut-off lines for p < 0.05, $log2 > 0.5).  What is 
immediately apparent is that a greater number of transcripts show downregulation than 
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upregulation in response to postnatal fluoxetine (117 vs. 30, chi-square p = 7.2 x 10-13).  This 
also holds true if the fold change criterion is more stringent ($log2 > 1; 16 vs. 6; p = 0.033).   
 
Figure 4.3 – Global Changes in Pet1/EYFP Gene Expression in PNFLX Mice 
 
 No significant alterations in the expression of any serotonergic genes were detected 
(figure 4.4), suggesting that alterations in SERT and Tph2 expression reported in prior studies 
are likely not occurring at the transcriptional level.  Sodium, calcium, or potassium channels 
were also not found to be differentially-expressed (appendix B, figure B.6), concordant with the 
lack of change in intrinsic electrophysiological properties reported in section 4.2.   
 Investigating the expression of other neurotransmitter receptors, we found no evidence 
for differential regulation of monoamine, acetylcholine, GABA, or glutamate receptors (figure 
4.5).  Among neuropeptides and their receptors, we identified a significant downregulation of the 















Gi-coupled neuropeptide Y receptor 2 (Npy2r) in postnatal fluoxetine-treated mice (48% of 
control, p = 0.017; figure 4.6).  Expression of Npy2r has been previously reported in the raphé, 
where it is believed to modulate 5-HT release as a presynaptic heteroreceptor (Kombian and 
Colmers, 1992; Stani% et al., 2011).   
 
 
Figure 4.4 – Expression of 5-HT receptors and genes in PNFLX mice 
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 No growth factors or regulators of neural development met the criteria for fold-change, 
although several transcripts showed significant changes of smaller magnitude (figure 4.7).  A 
symbol key and statistics for these genes is presented in table 4.2.  
 
Figure 4.7 – Expression of growth factors and regulators of neural development. 
 
Table 4.1 – Growth Factor and Regulators of Neural Development 
Symbol Name log2(ratio) % Control P value 
Cntn2 contactin 2 0.28 121% 0.001 
Dok4 docking protein 4 -0.28 82% 0.031 
Fgf1 fibroblast growth factor 1 -0.68 62% 0.020 
Fgfrl1 fibroblast growth factor receptor-like 1 0.27 121% 0.021 
Gfra1 glial cell line derived neurotrophic factor family receptor alpha 1 -0.43 74% 0.038 
Igf1 insulin-like growth factor 1 0.26 120% 0.032 
Itga3 integrin alpha 3 -0.37 77% 0.046 
Itga8 integrin alpha 8 0.14 110% 0.005 
Nrg1 neuregulin 1 -0.27 83% 0.048 
Prkg1 protein kinase, cGMP-dependent, type I 0.50 141% 0.041 
Rab23 RAB23, member RAS oncogene family -0.79 58% 0.024 
Tlx2 T-cell leukemia, homeobox 2 -0.23 85% 0.048 
Tulp3 tubby-like protein 3 0.29 122% 0.012 
Twist1 twist homolog 1 (Drosophila) 0.33 126% 0.034 
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 Among G proteins, signaling effectors, and modulators, we see three genes showing 
differential expression between treatment groups (figure 4.8): G protein gamma 13 (Gng13; 
391% of control, p = 0.017), Rho GTPase activating protein 27 (Arhgap27; 53% of control, p = 
0.045), and Rap guanine exchange factor 5 (Rapgef5; 53% of control, p = 0.041).  Gng13, as a 
gamma subunit, has been observed to interact with Go! and several " subunits; it binds to several 
proteins of the post-synaptic density (Li et al., 2006b), and is capable of modulating GIRK (G 
protein-coupled inwardly-rectifying K+) channels (Blake et al., 2001).  Arhgap27 acts as a 
GTPase activator for the small GTPase proteins Cdc42 and Rac1, and may participate in receptor 
endocytosis (Sakakibara et al., 2004).  Rapgef5 is an activator of Rap1 and Rap2, and is activated 
itself directly by cAMP.  Identified functions for signaling via Rapgef5’s EPAC family include 
regulation of cell division, differentiation, adhesion and migration (Borland et al., 2009); Rap1/2 
proteins have also been implicated in the removal of AMPA receptors in long-term plasticity 
(Stornetta and Zhu, 2011). 
 
Figure 4.8 – Expression G protein signaling transcripts in PNFLX mice 
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 Among genes thought to have a role in chromatin structure and DNA methylation, no 
transcripts met criteria for significance.  Histone cluster 3 H2ba (also known as histone cluster 1 
H2bb) did show a nearly 4-fold upregulation following PNFLX treatment, but did not reach 
statistical significance (p = 0.057). 
 
Figure 4.9 – Expression of epigenetic-related transcripts in PNFLX mice 
 
Table 4.2 – Legend and data for figure 4.9 
Symbol Name log2(ratio) % Control P value 
Cbx8 chromobox homolog 8 (Drosophila Pc class) 0.92 189% 0.146 
H2afv H2A histone family, member V 0.96 195% 0.070 
Hdac11 histone deacetylase 11 -0.71 61% 0.030 
Hist1h1t histone cluster 1, H1t 0.50 141% 0.002 
Hist2h2bb histone cluster 2, H2bb 0.16 112% 0.045 
Hist2h4 histone cluster 2, H4 -0.84 56% 0.128 
Hist3h2ba histone cluster 3, H2ba 1.99 398% 0.057 
Mbd1 methyl-CpG binding domain protein 1 -0.37 77% 0.022 
Myst2 MYST histone acetyltransferase 2 -0.30 81% 0.035 
Trdmt1 tRNA aspartic acid methyltransferase 1 -0.75 60% 0.022 
Trim27 tripartite motif-containing 27 -0.41 75% 0.046 
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 Finally, we sought to identify differentially expressed transcripts of classes for which no 
a priori prediction had been specified, using a somewhat more stringent two-fold cutoff.  A total 
of 22 genes met criteria (figure 4.10; table 4.3), of which Gng13 and Npy2r were previously 
discussed; the remainder are discussed below. 
 
Table 4.3 – Most differentially-expressed transcripts in PNFLX mice 
Symbol Name log2(ratio) % Control P value 
Gng13 guanine nucleotide binding protein (G protein), gamma 13 1.97 391% 0.017 
Zswim6 zinc finger, SWIM domain containing 6 1.46 276% 0.017 
Sfrp1 secreted frizzled-related protein 1 1.14 221% 0.014 
Ctss cathepsin S 1.13 219% 0.046 
Snap23 synaptosomal-associated protein 23 1.01 201% 0.003 
Suox sulfite oxidase 1.01 201% 0.039 
Oasl2 2'-5' oligoadenylate synthetase-like 2 -1.00 50% 0.011 
Nfxl1 nuclear transcription factor, X-box binding-like 1 -1.01 50% 0.026 
Srprb signal recognition particle receptor, B subunit -1.01 50% 0.020 
5730494N0
6Rik RIKEN cDNA 5730494N06 gene -1.04 49% 0.030 
Npy2r neuropeptide Y receptor Y2 -1.06 48% 0.017 
Prdx3 peroxiredoxin 3 -1.08 47% 0.014 
Mzt2 mitotic spindle organizing protein 2 -1.08 47% 0.005 
Zbtb25 zinc finger and BTB domain containing 25 -1.15 45% 0.007 
Nup54 nucleoporin 54 -1.16 45% 0.032 
Wdr53 WD repeat domain 53 -1.16 45% 0.012 
Olfr1330 olfactory receptor 1330 -1.25 42% 0.018 
Usp24 ubiquitin specific peptidase 24 -1.27 42% 0.037 
Rbm8a RNA binding motif protein 8a -1.28 41% 0.033 
H2-T22 histocompatibility 2, T region locus 22 -1.30 41% 0.023 
Mrpl22 mitochondrial ribosomal protein L22 -1.78 29% 0.031 




Figure 4.10 – Most differentially expressed genes in PNFLX mice 
 
Mitochondrial (arrows indicate upregulation or downregulation): 
! Suox (sulfite oxidase) – catalyzes the catabolism cysteine and methionine.  Deficiency of 
this enzyme leads to a neurological syndrome including seizures and altered muscle tone. 
" Mrpl22 (mitochondrial ribosomal protein L22) – Component of the large (39S) ribosomal 
subunit of the mitochondrion. 
" Prdx3 (periredoxin 3) – Antioxidant enzyme that reduces vulnerability to oxidative 
damage and apoptosis. 
RNA-binding: 
" Rbm8a (RNA binding motif 8A) – associated with splice junction sites in nuclear and 
cytoplasmic mRNA; thought to serve as a tag for post-splicing mRNA processing. 
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" Oasl2 (2’-5’ oligoadenylate synthetase-like 2) – unknown function (does not appear to 
have oligoadenylate synthetase activity); possibly involved in response to viral 
infection/interferon treatment. 
" Rbmxrt (RNA binding motif, X-linked) – a regulator of splice site selection; knock-down 
results in severe disruption of brain development (Tsend-Ayush et al., 2005) 
" Srprb (signal recognition particle receptor B subunit) – required for trafficking of 
membrane and secretory proteins to the endoplasmic reticulum. 
Zinc Finger motif: 
! Zswim6 (zinc finger, SWIM domain containing 6) – possible transcription factor. 
" Nfxl1 (nuclear transcription factor, X-box binding like-1) – probable transcription factor. 
" Zbtb25 (zinc finger and BTB binding domain containing 25)  -- transcriptional repressor 
of NF-AT (nuclear factor of activated T cells) responsive genes. 
Other: 
! Ctss (cathepsin S) – lysosomal cysteine protease; appears to have a role in inflammatory 
processes. 
! Sfrp1 (secreted frizzled-related protein 1) – secreted protein that antagonizes Wnt 
signaling, with a major role in brain development; tumor suppressor.  
! Snap23 (synaptosomal-associated protein 23kDa) – component of vesicular release 
machinery; localized to post-synaptic densities, where it may have a role in surface 
trafficking of NMDA receptors (Suh et al., 2010). 
" 5730494N06Rik – unknown transmembrane protein. 
" Mzt2 (mitotic spindle organizing protein 2B) – cytoskeletal protein involved in mitotic 
spindle formation. 
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" Nup54 (nucleoporin 54kDa) – component of the nuclear pore (allowing macromolecule 
export) 
" Wdr53 (WD repeat domain 53) – function unknown; possible involvement in ubiquitin E3 
ligase function & histone methylation. 
" Usp24 (ubiquitin specific peptidase 24) – cysteine protease involved in deubiquitination; 
has been associated with Parkinson’s disease risk in two genetic studies (Li et al., 2006a; Wu 
et al., 2010). 
" H2-T22 (histocompatibility 2, T region locus 22) – ligand for gamma-delta T cell receptor. 
 
Gene ontology analysis of the above 22 transcripts did not identify any significantly 
enriched functional categories, although this is not unusual for such a small set of genes.  Using a 
slightly lower threshold (1.75-fold rather than 2-fold) yields a list of 46 transcripts; these break 
into several enriched clusters: 
• Ribonucleoprotein complex/RNA binding ("Mrpl22, "Rbm8a, "Rbmxrt, "Srprb, 
"Eif2c1; p = 0.017) 
• mRNA metabolic process/splicing ("Rbm8a, "Rbmxrt, "Eif2c1, "Tsen2; p = 0.032) 
• Oxidoreductase/mitochondrial (!Suox, "Prdx3, "Ptgr2, "L2hgdh, "Dhrs7; p = 
0.033) 
• Regulation of translation/posttranscriptional ("Rbm8a, "Eif2c1, !Eefsec; p = 0.022) 





4.4 – Conclusions 
 
 In this chapter, we have characterized 5-HTergic neuron phenotypes of postnatal 
fluoxetine treated mice.  The density of serotonergic axonal projections to the prefrontal cortex 
and hippocampus is significantly reduced, in agreement with previous work reporting reduced 
SERT immunoreactivity in forebrain regions of (Maciag et al., 2006a).  These findings suggest 
that increases in 5-HT signaling during the innervation of the forebrain may lead to 
autoinhibitory feedback of developing projections.  While 5-HT appears to have trophic effects 
on non-serotonergic neurons, the literature suggests a homeostatic action of 5-HT on developing 
serotonergic neurons (described in Chapter 1). 
Our gene expression data indicates a predominance of downregulated transcripts, 
particularly those involved in mRNA processing and mitochondrial redox function.  One 
possible interpretation is that these changes are reflective of a ‘hypotrophic’ serotonin system; 
i.e., reduced axonal bulk and decreased activity may lead to reduced expression of genes 
involved in RNA and metabolic processes.  
In patch clamp recordings of DRN 5-HT neurons from PNFLX mice, the frequency of 
spontaneous IPSCs is increased, suggesting an increase in either the number or firing level of 
inhibitory inputs.  This finding provides us with a probable mechanism for the previously 
observed decrease in in vivo firing rate.  We found no major changes in intrinsic 
electrophysiological properties in PNFLX 5-HTergic neurons, in agreement with our failure to 
detect significant changes in ion channel expression in these cells. 
 Several of the genes identified in section 4.3 have interesting functions that, if replicated 
in an independent sample, suggest follow-up experiments.  The most strongly induced transcript, 
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Gng13, is both a modulator of G protein-coupled inwardly rectifying K+ channels (GIRK), and 
associated with the postsynaptic density.  As such, it is well poised to modulate activity in 
PNFLX 5-HTergic neurons.  Another upregulated transcript, secreted frizzled-related protein 1 
(Sfrp1), is a tumor suppressing inhibitor of the Wnt and BMP signaling pathways.  Its neuronal 
function has been studied mainly in early development, where it is critical in neural tube closure 
(Misra and Matise, 2010).  Sfrp1 also blocks Wnt7b-induced Rac activation, thus inhibiting 
dendritic development (Rosso et al., 2005).  If PNFLX induction of Sfrp1 were also found during 
postnatal development, it would suggest a potential mechanism by which postnatal SSRI 
blockade alters neurite morphology, in 5-HTergic and/or prefrontal and hippocampal pyramidal 
neurons.  Given the role of Sfrp1 in Rac signaling, the downregulation of Arhgap27 in PNFLX 
mice might be significant, as the protein encoded by this gene serves as a GTPase activator for 
Rac (Rebhun et al., 2000).   
 The downregulation of the neuropeptide Y receptor Y2 is also intriguing, given the 
evidence suggesting a role for NPY in stress and depression (Morales-Medina et al., 2010).  
Npy2r has been shown to function as an autoreceptor in NPY-releasing neurons (King et al., 
1999), and as a presynaptic heteroreceptor elsewhere (Qian et al., 1997).  Npy2r knockout mice 
show an anxiolytic-like phenotype in the elevated plus maze and open field tests (Redrobe et al., 
2003).  Notably, the antidepressant properties of exogenous NPY administration in the forced 
swim test are blocked by administration of TPH inhibitors, suggesting functional interaction of 
NPY and 5-HT in this paradigm (Redrobe et al., 2005).  In olfactory-bulbectomized mice, 
chronic administration of Y2 agonist or antagonist decreased or increased, respectively, 
immobility in the forced swim test (Morales-Medina et al., 2012).  While NPY signaling via the 
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Y2 receptor is clearly involved in depression-like behavior, the functional consequences of its 












 The selective serotonin reuptake inhibitors act on the serotonin transporter, a protein that 
is only expressed on serotonergic neurons in the adult CNS.  Beyond desensitization of 5-HT1A 
autoreceptors, little is known about the effect of chronic SSRI treatment on 5-HTergic neurons of 
the raphé.  In this chapter, results of two studies investigating the action of SSRI treatment on the 
raphé nuclei are presented: first, positron emission tomographic (PET) measurement of 5-HT1A 
binding sites in major depression before and during SSRI treatment; and the second, an analysis 
of gene expression in serotonergic dorsal raphé neurons of mice treated with fluoxetine. 
Acute treatment with SSRI increases 5-HT levels throughout the brain, leading to 
intensified signaling through 5-HT receptors of all types.  In the raphé, this leads to enhanced 
autoinhibition via somatodendritic 5-HT1A receptors, suppressing the firing rate of 5-HT neurons.  
With chronic treatment, somatodendritic 5-HT1A receptors desensitize, allowing 5-HT neurons to 
return to their normal firing frequency.  As described in the first chapter, PET studies have 
shown that depressed patients who have not been recently treated show elevated 5-HT1A binding 
(in both raphé and projection regions), while those that are currently, or have recently been, on 
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SSRIs do not.  A number of open questions remain about this observation: what is the time 
course of this apparent downregulation?  Does the degree of downregulation correlate with 
treatment response?  Does this downregulation relate to the prior observation that increased 5-
HT1A binding predicts poor treatment response?  
 
5.1 – Positron emission tomography of 5-HT1A binding during SSRI treatment 
 
 Previous data from our group has suggested a model in which elevated 5-HT1A binding is 
a trait abnormality in major depressive disorder, and is normalized by SSRI treatment (Miller et 
al., 2009c; Parsey et al., 2010).  Coupled with the preclinical and clinical evidence for 
autoreceptor desensitization, this suggests the possibility that downregulation of 5-HT1A 
receptors in the raphé may be important in the clinical response.  We therefore sought to image 
this longitudinally in depressed subjects, in order to: a) provide causal evidence for SSRI-
induced downregulation; b) define the timeline over which this downregulation occurs; and c) 
test whether autoreceptor downregulation is related to the clinical response. 
  Twenty-three subjects with a current major depressive episode were scanned with the 5-
HT1A radioligand [11C]-WAY-100635, before and after treatment with paroxetine, citalopram, or 
escitalopram (table 5.1).  Because our previous studies have suggested that SSRI effects may 
persist for months or years after cessation, four subjects with history of antidepressant treatment 
within the prior four years were excluded from some analyses.  One subject did not complete a 




Table 5.1 – Subjects characteristics, Hamilton Depression Rating Scale (HDRS) scores, and 
radiochemical characteristics.  Means are shown with percentage or ± standard deviation. 
 
 There was a 52% mean reduction in the 24-item HDRS score (pre-treatment HDRS = 
24.3 ± 7.2; post-treatment HDRS = 11.7 ± 7.5; p < 0.001; paired-samples t-test).  When testing 
the entire sample as one group linear mixed-effects model we found no effect of short-term SSRI 
treatment on raphé binding (df=1:22; F=2.579; p=0.1225).  Importantly however, when 
removing subjects (n=4) with known recent history of prior SSRI exposure, 5-HT1A BPF in the 
raphe was reduced 18% in response to SSRI treatment (figure 5.1; df=1:18; F=5.12; p=0.036).  
However, reduction in 5-HT1A BPF did not correlate with change in HDRS scores (df=1; F=0.48; 
p=0.5). 
 In accord with previous work from the laboratory, we found that SSRI treatment leads to 
a reduction of 5-HT1A binding in depressed subjects.  However, we failed to detect a relationship 
to clinical response, largely in agreement with the prior finding that elevated 5-HT1A binding is 
visible in both remitted and acute depression.  Together, these data suggest that either a) 
autoreceptor desensitization is mediated by changes in binding, which have no bearing on 
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clinical response, or b) autoreceptor desensitization occurs independently of protein expression, 




Figure 5.1 – Altered raphé 5-HT1A binding following chronic SSRI treatment.  Binding potential 
(BPF) of depressed subjects before and after treatment with SSRI (n=19).  Four subjects with a 




















5.2 – Transcriptional alterations following SSRI treatment 
 
 Because of the gradual onset of SSRI clinical response, it has long been postulated that 
adaptive changes in response to elevated 5-HT levels are involved.  Numerous theories have 
been proposed, such as the autoreceptor desensitization hypothesis.  Because both SERT and 5-
HT1A autoreceptors are highly expressed in the raphé, serotonergic neurons are a prime candidate 
for such adaptations.  Many have already been described, such as the desensitization of 5-HT1A 
and the reduced expression of SERT.  We sought to further characterize adaptive responses of 
DRN serotonergic neurons to chronic SSRI treatment through the use of gene expression 
profiling. 
 
Figure 5.2 – Gene expression changes following fluoxetine treatment 
 















 Initial analysis focused on the expression of serotonergic genes, since 5-HT1A and SERT 
both appear to be regulated by SSRI treatment.  Unexpectedly, we found no evidence of altered 
expression of any members of this class (figure 5.3) using our specified criteria (p < 0.05, 0.75 
fold-change).   
 Because the electrophysiological properties of serotonergic neurons are altered during 
SSRI treatment, we further explored the expression of ion channels and neurotransmitter 
receptors.  Among ion channels, no transcripts met both criteria test criteria (figure 5.4), although 
potassium voltage-gated channel, Isk-related subfamily, gene 2 (Kcne2) did show a modest 
downregulation (75.9% of saline group; p = 0.023).  Likewise, neurotransmitter receptors were 
not significantly altered by fluoxetine treatment (figure 5.5), with glycine receptor subunit !2 
(Glra2) slightly downregulated (75.8% of saline group; p = 0.032).  No changes in expression 





Figure 5.3 – Serotonergic gene expression following chronic fluoxetine treatment
 
Figure 5.4 – Ion channel expression following chronic fluoxetine treatment 
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Figure 5.5 – Neurotransmitter receptor expression following chronic fluoxetine 
 
 In rodent studies of 5-HT1A desensitization, a causative mechanism has not been 
definitively identified; actual reductions of binding or mRNA expression have only been 
observed in animal models, and receptor internalization is far too rapid to account for the 
timeline over which desensitization occurs.  We thus investigated regulators of G protein 
signaling for altered expression following chronic fluoxetine treatment (figure 5.6).  Rho GTPase 
activating protein 18 showed significant upregulation (209% of control; p = 0.027).  This 
transcript encodes a suppressor of RhoA activity, and modulates the cytoskeleton in processes 
including migration, adhesion, and cell shape formation (Maeda et al., 2011); SNPs within this 
gene have been associated with schizophrenia and dorsolateral PFC activation during the Serial 
Item Recognition Paradigm (Potkin et al., 2009).  Regulator of G protein signaling 17 (Rgs17; 
Rgsz2) was modestly but significantly upregulated as well (152% of control; p = 0.011).  Rgs17 
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acts as a GTPase inhibitor of Gi, Go, and Gz proteins (Mao et al., 2004); a mutation in the RGS 
interacting site of G!i2 has been shown to increase sensitivity to SSRI or 5-HT1A agonist (Talbot 
et al., 2010).   
 
Figure 5.6 – Expression of regulators of G protein signaling following chronic fluoxetine 
 
 Chronic SSRI treatment has trophic actions in projection regions such as the 
hippocampus, but such effects have, to our knowledge, not been investigated in serotonergic 
neurons themselves.  We therefore examined the expression of growth factors/receptors (figure 
5.7) and proteins regulating apoptotic activity (figure 5.8).  Among the growth factor-related 
genes, the only transcript showing significant differential expression was opioid growth factor 
receptor-like 1 (Ogfrl1; 224% of control, p = 0.034), an orphan receptor with 43% homology to 
the metenkephalin-responsive opioid growth factor receptor.  
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Figure 5.7 – Growth factor/receptor expression following chronic fluoxetine 
 
 Several genes involved in apoptosis showed limited effects of fluoxetine treatment, but 
only high-mobility group box 1 (Hmgb1; amphoterin) met both statistical and magnitude 
significance (table 5.2).  Hmgb1 is both a transcription factor and a cytokine, mediating 
proinflammatory effects through the receptor for advanced glycation end products (Rage) and 
Toll-like receptors.  Its role in the brain is complex and not well understood: expression is 
highest during development, and genetic knockdown leads to increased neural apoptosis (Zhao et 





Figure 5.8 – Expression of apoptosis regulators following chronic fluoxetine 
 
Table 5.2 – Expression of genes regulating apoptosis following chronic fluoxetine 
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 We finally investigated the possibility that members of gene classes for which we had no 
a priori hypothesis might be differentially-expressed following chronic fluoxetine treatment.  
Transcripts meeting the criteria (p < 0.05; >200% or <50% of controls) are plotted in figure 5.9 
and listed in table 5.3.  Among these genes, Ogfrl1 and Arhgap18 were discussed above. 
 
Figure 5.9 – Genes most differentially-expressed following chronic fluoxetine 
 !  
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Table 5.3 – Genes most differentially-expressed following chronic fluoxetine 
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Gene ontology analysis of this list reveals three clusters of enriched genes: 
1. Zinc ion binding: !Dctd, "Adnp2, !Gm5136, !Rnf152, !Rnf5, "Mt2, "Rnf113A1, 
!Unc13c (p = 0.00184). 
2. Zing finger domain: "Adnp2, !Rnf152, !Rnf5, "Rnf113a1, !Unc13c (p = 0.020). 
3. Endomembrane/intracellular transport: "Golga7, !Pigm, !Bet1, "Nup54 (p = 0.0039). 
 
 
Presented here are brief descriptions of these genes: 
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! cCMP deaminase (Dctd) – catalyzes synthesis of dUMP, the substrate for dTMP 
synthesis (DNA repair and replication).   
" ADNP homeobox 2 (Adnp2) – homologue of activity-dependent neuroprotective 
protein; siRNA knockdown increases susceptibility to oxidative stress in the P19 
neuronal/glial-like cell line (Kushnir et al., 2008). 
! Gm5136 – predicted metallopeptidase 
! Rnf152 – E3 ubiquitin ligase; targets protein degradation; overexpression leads to 
apoptosis (Zhang et al., 2010). 
! Rnf5 – E3 ubiquitin ligase; associated with both endoplasmic reticulum-based 
degradation of misfolded proteins and cytoskeletal modulation (Didier et al., 2003; 
Tcherpakov et al., 2009) 
" Metallothionein 2 (Mt2) – a matrix metallopeptidase involved in regulation, 
metabolism, and detoxification of heavy metals (esp. zinc and copper); protective against 
"-amyloid aggregation and reactive oxygen species-mediated cell death (Reinecke et al., 
2006; Chung et al., 2010).   
" Rnf113a1 – unknown function; protein-protein interaction zinc finger domain. 
! Unc13c – Synaptic vesicle-associated syntaxin binding partner; potentially involved 
in plasticity (Yang et al., 2007). 
" Golgin A7 (Golga7) – involved in Golgi-to-cell membrane transport, via 
palmitoylation of membrane proteins. 
! Phosphatidylinositol glycan anchor biosynthesis class M (Pigm) – ER protein that 
provides glycosylphosphatidylinositol (GPI) linkages for membrane proteins. 
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! Blocked early in transport homolog 1 (Bet1) – Involved in vesicular transport from 
ER to Golgi. 
" Nucleoporin 54kDa (Nup54) – component of nuclear pore, allowing macromolecules 
such as mRNA to exit.   
! Kelch repeat and BTB (POZ) domain containing 3 (Kbtbd3) – Unknown; possible 
transcription factor? 
! Homer2 – postsynaptic binding partner of metabotropic glutamate receptors; 
mediates RGS protein action on metabotropic receptors and synaptic plasticity (Shin et 
al., 2003; Szumlinski et al., 2008). 
! Ccl25 – Member of CC cytokine family; enhancer of metalloproteinase expression 
implicated in cell migration. 
! Jumonji domain containing 8 (Jmjd8) – Unknown; likely transcription factor. 






5.3 – Postnatal fluoxetine as a model of treatment-resistant depression 
 
 The conflicting effects of postnatal and adult treatment with fluoxetine on emotional 
behavior pose an interesting question: can the phenotype of PNFLX mice be rescued by SSRI 
treatment in adulthood?  Unexpectedly, in the novelty-suppressed feeding test, chronic fluoxetine 
actually increases the latency to feed in PNFLX mice (figure 5.10, unpublished data).  No effect 
of either treatment on weight loss or home cage food consumption was detected.  These data 
suggest that PNFLX can be conceptualized as a model of treatment-resistant depression.  It may 
be speculated that the above-mentioned ‘hypotrophic’ 5-HT system elicited by PNFLX treatment 
impairs the ability of adult SERT blockade to alter 5-HT signaling in relevant limbic regions. 
 
Figure 5.10 – Effects of postnatal x adult fluoxetine in novelty-suppressed feeding test 
 
 
 We therefore sought to identify transcripts that were selectively regulated by adult 
fluoxetine in PN-saline treated mice, but not in PN-FLX mice.  Microarray data from the 
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postnatal saline/adult fluoxetine (pSaF) group were contrasted against the pSaS, pFaS, and pFaF 
groups, to find expression of genes that most closely follow the antidepressant phenotype.   
 First, the previously identified ‘hits’ for adult fluoxetine treatment were analyzed (figure 
5.11).  Of the 19 originally identified genes, nine retain statistically significant alteration.  We 
also again investigated expression of serotonergic genes; as previously, no significant changes in 
expression were detected (figure 5.12).   
 Investigating transcripts most significantly different in this comparison (figure 5.13; table 
5.4), we see a preponderance of upregulated genes (11 vs. 3, chi-square p = 0.033).  Besides the 
nine originally identified, there are several further genes of interest. 
 




Figure 5.12 – Expression of 5-HTergic genes, pSaF vs other groups 
 
Figure 5.13 – Most strongly regulated transcripts, pSaF vs. other groups 
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Table 5.4 – Transcripts most strongly regulated in pSaF mice 
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Brief descriptions of the genes not presented earlier are presented here: 
! BC003266 (C1orf212) – unknown; probable membrane protein. 
! Endothelin converting enzyme 2 (Ece2) – Involved in the synthesis of many peptide 
transmitters, including endothelin, neurotensin, angiotensin I, substance P, and proenkephalin- 
and prodynorphin-derived peptides.  Knockout mice display impaired learning and memory 
(Rodriguiz et al., 2008). 
! Zinc finger, matrin type 4 (Zmat4) – Unknown function.  Domain structure suggests binding 
to nucleic acid binding.  Copy number variation has been associated with hematological 
malignancy (Wan et al., 2011).   
! Ribosomal protein S18 (Rps18) – component of the 40S subunit; binds the cytoskeletal 
protein cofilin (Kusui et al., 2004).   
! Histamine receptor 2 (Hrh2) – G protein coupled receptor, linked to both PKA and PKC 
activation.   
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! Vesicular glutamate transporter 3 (Slc17a8) – Loads glutamate into synaptic vesicles; 
colocalizes with Vmat2 and 5-HT in hippocampal axon varicosities. 
 
Functional annotation clustering revealed a single category enriched among these 13 genes: Zinc 
binding/zinc finger motif, including !Dctd, "Adnp2, !Ece2, !Rnf152, !Zmat4, !Rnf5, 









5.4 – Conclusions 
 In this chapter I have presented the findings of two experiments investigating the effect of 
chronic SSRI administration on serotonergic neurons of the raphé.  In subjects with major 
depression, chronic treatment with citalopram or paroxetine led to a decrease in 5-HT1A receptor 
binding within the raphé, but only after subjects with a history of recent antidepressant 
medication were excluded.  These findings provide causal evidence to prior studies from our 
group reporting elevated 5-HT1A binding in medication-naïve, but not recently medicated 
depressed patients (Parsey et al., 2006a; Parsey et al., 2010), further corroborating our present 
model: elevated 5-HT1A autoreceptor expression is a trait of major depression which is 
normalized by SSRI treatment.  
 The lack of correlation between downregulation of 5-HT1A receptor in the raphé and 
clinical response runs counter to our initial hypothesis.  On one hand, our sample size was small, 
so the study might not have been sufficiently powered to detect a relationship.  On the other hand, 
5-HT1A receptor downregulation might be an epiphenomenon of antidepressant treatment.  
Supporting the latter interpretation, 5-HT1A overexpression in depressed subjects may be 
independent of current mood state (Miller et al., 2009a), although in this study, raphé 5-HT1A 
binding of remitted patients was intermediate between controls and acutely-depressed subjects. 
 In the gene expression analysis, a number of transcripts were identified as differentially 
expressed.  Notably absent were changes in serotonin-related genes, seemingly at odds with the 
above finding and the literature.  As discussed in the introduction, fluoxetine downregulation of 
SERT is thought to be mediated by miR-16 (Baudry et al., 2010).  It therefore seems likely that 
miR-16 is acting through a translation-inhibiting mechanism rather than an mRNA-degrading 
mechanism, which would account for the discrepancy between mRNA and protein.  The failure 
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to detect 5-HT1A downregulation was expected, based on the literature: while desensitization is 
commonly reported, a downregulation of autoreceptor expression has only been reported in 














 In this work, we have presented the transcriptome of serotonergic neurons, as well as the 
actions of serotonin selective reuptake inhibitors on the serotonergic neurons of the raphé.  We 
report, to our knowledge, the first comparative study of gene expression in adult dorsal raphé 5-
HT neurons.  During a postnatal critical period in which SSRI treatment induces an anxiety- and 
depression-like phenotype, we identified alterations in the anatomy, physiology, and gene 
expression of 5-HTergic neurons.  In adulthood, when SSRI treatment has anxiolytic and 
antidepressant effects, we have likewise described changes in gene expression, and in raphé 5-
HT1A binding in depressed subjects.  
 
6.1 – Transcriptome of serotonergic neurons 
 In comparing ePet-EYFP labeled dorsal raphé neurons with whole brain homogenate, we 
found substantial and highly significant enrichment of transcripts known to be highly expressed 
in serotonergic neurons (e.g., SERT, TPH, aromatic amino acid decarboxylase), providing us 
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with a positive control data set.  We next interrogated the microarray data set for gene classes of 
interest.  Among specifiers of serotonergic cell fate, we found several genes that remained 
expressed into adulthood (Pet1, GATA2, GATA3, Lmx1b), suggesting that these transcription 
factors may have continuing importance in serotonergic neuron function.  Among 
neurotransmitter receptors and ion channels, we identified several transcripts that are enriched in 
5-HT neurons, including the sodium channel subunit Scn9a, the glycine receptor subunits Glra1 
and Glra2, and the AMPA subunit Gria4.  Notably, we found particularly high expression of the 
glutamate vesicular transporter Vglut3 (Slc17a8), which later emerged as a potential target of 
adult fluoxetine treatment. 
 In gene ontology analysis of 5-HT neuron-enriched transcripts, we found 
overrepresentation of biogenic amine synthetic and neurotransmitter transport genes, as 
anticipated.  Overrepresentation of ribosomal and mitochondrial genes likely reflects the 
increased protein synthetic and energetic requirements of neurons with extensive axonal 
distribution.  The analysis with our collaborators of noradrenergic locus coeruleus neurons will 
either support or refute this hypothesis.   
 We also identified a number of novel transcripts overrepresented in raphé samples, 
corroborated by in situ hybridization data from the Allen Brain Atlas.  These include the 
interleukin receptor Il1r1, prostaglandin E2 synthase 3, the lens structural protein crystallin-"A2, 
and ubiquitin C.  With further validation, these genes may elucidate idiosyncrasies of 
serotonergic neuron function.  Several genes identified as enriched appeared to show subset 
specific distributions in the in situ images, such as the ubiquitin ligase complex protein Asb4 and 
the AMPA receptor subunit Gria4.  These data define functional subtypes of serotonergic 
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neurons; future work could identify other subgroup specific properties such as projection targets 
or electrophysiological properties. 
 
6.2 – Postnatal fluoxetine 
 There are substantial data on the behavioral phenotype caused by postnatal exposure to 
serotonin reuptake inhibitors: increased anxiety-like behavior, reduced mobility in the forced 
swim test (Ansorge et al., 2004), reduced social interaction and aggression (Rodriguez Echandia 
and Broitman, 1983a; Vogel et al., 1988), reduced sexual behavior in males (Neill et al., 1990), 
and disruption of REM sleep (Popa et al., 2008).  However, little is known about the biological 
mechanisms underlying this phenotype.  We therefore sought to characterize the effects of 
postnatal fluoxetine treatment on serotonergic neurons. 
 Because of the autoregulatory role of serotonin during development, we investigated the 
anatomy of serotonergic neurons in PNFLX mice.  Although we found no reductions in 
serotonergic cell number, the density of serotonergic fibers was significantly reduced in 
prefrontal cortex and the CA3 region of the hippocampus.  The mechanism of this effect 
presently unknown, but could result from the direct action of increased extracellular serotonin on 
somatodendritic 5-HT1A and/or axonal growth cone 5-HT1B receptors (e.g., Whitaker-Azmitia 
and Azmitia, 1986a; Jonakait et al., 1988; Rumajogee et al., 2004).  Alternatively, serotonin 
activation of receptors in target brain regions may lead to changes in secreted or cell surface 
markers that provide growth inhibitory signals developing serotonergic axons.  Future work 
should be directed towards distinguishing between these possibilities. 
Based on the reduced basal firing rate of 5-HT neurons in PNFLX mice, we used patch-
clamp recording to study their electrophysiological properties in greater depth, suggesting that 
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the previously observed reduction in basal firing seen in anesthetized mice is mediated by an 
increase in inhibitory tone.  No evidence to support a change in intrinsic electrophysiological 
properties of vmDR 5-HT neurons was found, including resting membrane potential, action 
potential threshold, and input-output relationship.  Rather, an increase in the frequency of 
inhibitory post-synaptic currents was observed.  Because the increase in iPSCs was seen in slice, 
the source of these inputs is presumably local interneurons or nearby structures within the 
brainstem.  Future work, both in vivo and in slice, can elucidate the neuronal population 
responsible for this phenomenon.   
 The general pattern of gene expression changes in PNFLX mice is compatible with other 
data in this model, from this and other studies.  The absence of any change in ion channel and 
canonical neurotransmitter expression is in agreement with electrophysiological findings, and in 
combination further support the reduction of in vivo firing rate as a circuit-mediated effect.  We 
found that there was a significantly greater number of downregulated versus upregulated 
transcripts.  There was also notable downregulation of transcripts involved in mitochondrial 
redox and mRNA processing; we posit that, given the combination of reduced axonal density in 
projection regions and reduced activity, these data reflect a decrease in demand for production of 
these enyzmes.   
Reduced immunoreactivity for Tph2 and SERT has been reported in postnatal SSRI-
treated mice (Maciag et al., 2006c).  This discrepancy could be due to post-transcriptional 
alterations of protein expression (e.g., enhanced protein degradation, miRNA inhibition of 
translation, etc), or alternatively may reflect differences in the treatment paradigm (fluoxetine 
from P2-P11 vs. citalopram from P8-P21).  
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 As discussed previously, a number of intriguing transcripts were identified in the gene 
expression profile of PNFLX 5-HT neurons.  The G protein gamma subunit Gng13 was induced 
nearly 4-fold by postnatal fluoxetine treatment.  Because of its localization to the postsynaptic 
density and reported activation of GIRK channels (Blake et al., 2001), the observed upregulation 
may be quite important to metabotropic Gi/o-coupled receptor signaling.  The secreted antagonist 
of Wnt signaling, Sfrp1, is of interest in light of the observed reduction in axonal density.  
Inhibition of Wnt7b-mediated Rac activation by Sfrp1 suppresses dendritic growth in cultured 
hippocampal neurons; upregulation of Sfrp1 expression in 5-HT neurons during PNFLX 
treatment could account for altered dendritic formation in the prefrontal cortex and hippocampus 
(Tahilia Rebello, personal communication), and/or inhibit 5-HTergic axon formation via an 
autocrine mechanism.   
  
 
6.3 – Adult SSRI treatment 
  
 We report here downregulation of 5-HT1A receptor binding in the raphé of depressed 
subjects without a history of recent medication.  These findings are in agreement with previous 
work from our laboratory showing that medication-naïve depressed patients have elevated 5-
HT1A binding, but those who were recently on medication do not (Parsey et al., 2006a; Miller et 
al., 2009a; Parsey et al., 2010).  The upregulation of 5-HT1A appears to be a trait abnormality, as 
expression levels are similar in not recently medicated subjects regardless of current mood state 
(Miller et al., 2009a).  At present, we do not yet know how long the SSRI-induced 
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downregulation of 5-HT1A binding persists after treatment cessation, but it appears to be at least 
several months.   
 The findings of this and previous studies from our laboratory are at odds with earlier 
work, in which authors reported reduced 5-HT1A binding in depression (Drevets et al., 1999; 
Sargent et al., 2000; Bhagwagar et al., 2004a).  This apparent discrepancy has recently been 
explained by methodological differences (Parsey et al., 2010).  Briefly, analysis in our studies 
has used BPF as outcome measure, defined as (VROI – VRR)/fp, where VROI is the volume of 
distribution in the target tissue, VRR is the non-specific binding in a reference region, and fp is the 
fraction of plasma radioligand that is free (unbound to proteins/blood cells; i.e., the fraction that 
is able to cross the blood-brain barrier).  Other groups have used BPND as an outcome measure, 
defined as (VROI – VRR)/VRR.  This measure is more sensitive to variation in reference tissue 
binding, particularly with ligands such as WAY-100635 in which VRR is extremely low, due to 
the presence of VRR in the denominator.  Because prior studies have used reference regions 
including cerebellar gray matter, in which small amounts of 5-HT1A have been found (Parsey et 
al., 2005b), subtle changes in reference region binding can profoundly affect binding estimates 
for all other regions.  Indeed, when our data was reanalyzed using BPND as the outcome measure 
and cerebellar gray matter is included in the reference region, we also found reduced 5-HT1A 
binding in unmedicated depression.  Further analysis revealed that 5-HT1A binding in cerebellar 
gray matter was elevated in depressed subjects, which would lead to underestimation of specific 
binding in other regions when using BPND (Parsey et al., 2010). 
 Two studies have investigated the effect of SSRI treatment on 5-HT1A binding in 
depressed subjects.  As part of a larger study on MDD, Sargent et al rescanned 10 subjects after a 
median 14 weeks an SSRI treatment, and found a similar 15-20% but statistically nonsignificant 
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decrease in BPND (Sargent et al., 2000).  Likewise, no changes in BPND were found in 15 MDD 
patients scanned before and after a median 9.4 weeks treatment with an SSRI or venlafaxine 
(Moses-Kolko et al., 2007).  Beyond having a larger sample size, the methodological issues 
discussed above also differentiate the current study from these prior studies.   
 As discussed in the introduction, the difference between autoreceptor desensitization and 
downregulation must be emphasized.  While autoreceptor desensitization has been observed in a 
variety of rodent and clinical studies, downregulation of receptor binding appears to be unique to 
depression or a depression-like state.  Beyond the clinical data presented here, 5-HT1A expression 
has been reported to be increased in animal models of depression, and downregulated following 
SSRI treatment (Naudon et al., 2002b; Günther et al., 2008).  Theoretically, control subjects 
imaged for 5-HT1A binding before and after SSRI treatment would be expected not to show 
downregulation, although such as study is unlikely due to ethical considerations (i.e., multiple 
radiation exposures and chronic drug treatment in healthy volunteers).   
  As discussed in chapter 5, the failure to detect a relationship between raphé 5-HT1A 
downregulation and clinical response was not expected.  Whether this is due to a lack of power 
in the present study, or evidence that downregulation is unrelated to treatment response will have 
to be determined in future studies.   
 In our study of gene expression responses to adult fluoxetine treatment, we did not detect 
any change in mRNA abundance of serotonin receptors or SERT.  That lack of change in 5-HT1A 
is in agreement with our model of SSRI induced downregulation being unique to models of 
depression in which it is upregulated to begin with.  That SERT mRNA is not altered, while 
many studies report reduced binding, is consistent with a post-mRNA level regulation, which 
may be mediated by miR-16 inhibition of translation (Baudry et al., 2010).   
! "#&!
Of the transcripts identified, we believe the transcripts that showed upregulation in 
PNSAL but not PNFLX mice are the most promising, as PNFLX mice do not show typical 
antidepressant responses in behavioral measures.  The finding that Vglut3 is upregulated by 
chronic fluoxetine is particularly notable, given that this gene was enriched in 5-HTergic neuron 
samples vs whole brain. Vglut3 in the raphé shows colocalization with 5-HT immunoreactivity 
in terminals, but relatively little colocalization with SERT (Shutoh et al., 2008), suggesting that a 
specific subset of axon terminals are targeted for its expression.  Mice lacking Vglut3 show 
elevated anxiety-like behavior, reduced autoreceptor sensitivity in the 5-HT1A-agonist induced 
hypothermia test, and reduced hippocampal 5-HT efflux (Amilhon et al., 2010).  The role of 
Vglut3 in 5-HT neuron function has not been definitively identified, but is likely either co-
release of glutamate and/or enhanced packaging of 5-HT into vesicles (El Mestikawy et al., 
2011).  It is difficult to speculate why Vglut3 is not upregulated by chronic SSRI in PNFLX mice, 
but the potential consequences on 5-HTergic neurons to release 5-HT and/or glutamate is clear. 
 The upregulation of endothelin converting enzyme 2 (Ece2) is also notable.  A number of 
neuropeptides are expressed in raphé, with varying colocalization with 5-HT markers (Fu et al., 
2010).  While we did not identify any neuropeptides showing significantly altered expression, 
the upregulation of a synthetic enzyme is suggestive that processing or release may be effected. 
 Upregulation of the histamine receptor 2 may be significant as well.  The relationship 
between serotonergic function and sleep/wakefulness is well characterized (Monti, 2010), and 
may relate to sleep abnormalities in depression.  H2 has been observed to activate both PKA and 
PKC signaling pathways, and it is not known which coupling may be present in the raphé.  
Further work should be directed to confirming whether DRN 5-HT neurons of SSRI-treated mice 
are indeed more sensitive to histamine transmission, and what biological effect this might have. 
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 In conclusion, we have identified a number of biological effects of SSRI treatment on the 
raphé, both during development and adulthood.  While these results are correlational in nature, 
the neurobiological alterations identified will form the foundation for future mechanistic studies, 
and improve our understanding of how this drug class exerts its behavioral effects.  
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Appendix B: Supplemental Data 
 
B.1 – Allen Brain Atlas Entries for Selected Genes 
 In this section, in situ hybridization images are presented for selected genes from the 
expression profiling experiments.  As a reference, figure B.1 highlights the signal of Tph2 
mRNA in both sagittal and coronal planes (for many genes, only sagittal sections are available).  






Figure B.1 – In situ hybridization of Tph2 mRNA from the Allen Brain Atlas (www.brain-
map.org). Full sagittal view (top left) with inset (top right); coronal sections through rostral 




Figure B.2 – ISH images of selected transcripts in DRN: genes involved in specification of 
serotonergic cell fate (Gata2, Gata2, Lmx1b, Pet1/Fev) and those for which serotonergic 
expression was unknown (MAOA, 5-HT1D). 




Figure B.4 – Volcano Plot of Synapse-Associated Genes, 5-HT DRN vs Brain 
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Figure B.5 – Volcano Plot of Growth Factors/Neurotrophins and Receptors 
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Table B.1 – Pet1-DRN overrepresented genes (fold change +8, p < 0.001) 
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Figure B.7: No changes in ion channel expression in PNFLX mice 
 
